Synthesis of Dihydroisoquinolinone-4-methylboronic Esters via Domino Heck/borylation using a Structurally Characterized Palladacycle as a Catalyst

M. Jhansi Rani and N. Dastagiri Reddy*

Department of Chemistry, Pondicherry University, Pondicherry 605014, India

ndreddy.che@pondiuni.edu.in

Supporting Information

Table of contents

- 1. General information
- 2. Optimization of base and solvents
- 3. Synthesis of Imidazolium salt
- 4. Synthesis of palladacycle [Pd(CAC:)(PPh₃)Cl]
- 5. General procedure for the synthesis of the substrates
- 6. General procedure for Heck/Borylation reactions
- 7. Synthesis of 7a & 7b
- 8. Characterization of the compounds
- 9. Crystal data of [Pd(CAC:)(PPh₃)Cl] and 20
- 10. References
- 11. NMR Spectra

1. General Information.

All the chemicals were purchased from commercial sources and used without further purification unless otherwise stated. Reactions were monitored by analytical thin-layer chromatography (TLC). Purification of the products was done by column chromatography with 100–200 mesh silica gel. Melting points were determined on a melting point apparatus in open capillaries. Infrared spectra of samples were recorded from 4000 to 500 cm⁻¹ in ATR (attenuated total reflectance) mode using a Thermo Nicolet 6700 FT-IR spectrometer. ¹H, ¹³C and ³¹P spectra were recorded on a Bruker 400 MHz instrument. ¹⁹F spectra were recorded on a Bruker 500 MHz instrument. Unless otherwise stated, deuterochloroform (CDCl₃) was used as solvents. Chemical shifts (δ) for hydrogen and carbon resonances are reported in parts per million and are referenced to the hydrogen and carbon resonance of the solvent CHCl₃ (δ = 7.26 ppm and δ = 77.16 ppm) and DMSO (δ = 2.5 ppm and δ = 39.5 ppm). The splitting patterns are reported as s (singlet), d (doublet), dd (doublet of a doublet), td (triplet of a doublet), t (triplet), q (quartet), br (broad), and m (multiplet). Coupling constants are given in hertz. Highresolution mass spectra were recorded on an Agilent 6540 UHD Q-TOF mass spectrometer equipped with an electrospray ion source (ESI), operated in the positive mode. Elemental analyses were performed using a Thermo Scientific Flash 2000 CHNS analyzer. N-Methyl-N-(2-methylallyl)benzamide,¹ bromobenzamides,²⁻⁷ 2-bromo-N-(2-phenylallyl)benzamide,⁸ Nphenylmethacrylamide, 9 (Z)-N-methoxy-2,3-diphenylacrylamide, 10 and substrates **5a** – **f** were prepared by following methods reported in the literature.¹¹⁻¹³

2. Table S1. Optimization of Base and Solvents^a



3	Et ₃ N	DCE	90	0
4	Na ₂ CO ₃	DCE	90	89
5	KO ^t Bu	DCE	90	0
6	KOAC	DCE	90	62
7	K ₃ PO ₄	DCE	90	80
8	K ₂ CO ₃	MeCN	60	43
9	K ₂ CO ₃	DMF	90	10
10	K ₂ CO ₃	H ₂ O	90	16
11	K ₂ CO ₃	THF	90	<5
12	K ₂ CO ₃	PhMe	90	78
13	K ₂ CO ₃	DMA	90	60
14	K ₂ CO ₃	DMSO	90	0
15	K ₂ CO ₃	1,4-Dioxane	60	35
16	K ₂ CO ₃	DCE/H ₂ O (2.5 mL/0.5 mL)	90	94
17	K ₂ CO ₃	PhMe/H ₂ O (2.5 mL/0.5 mL)	90	84
18	K ₂ CO ₃	MeCN/H ₂ O (2.5 mL/0.5 mL)	90	0
19	K ₂ CO ₃	1,4-Dioxane/H ₂ O (2.5 mL/0.5 mL)	90	0

^{*a*} Reaction conditions: **1a** (0.5 mmol), $B_2(Pin)_2$ (1.0 mmol), $[Pd(C\wedge C:)(PPh_3)Cl]$ (1 mol%), Base (1.0 mmol), and Solvent (3 mL), 90 °C under N₂ for 6 h. ^{*b*}Isolated yield.

3. Synthesis of imidazolium salt (ImidHCl).

To a mixture of 2-chloro-3-(1H-imidazol-1-yl)quinoxaline (0.231 g, 1 mmol) and 2-chloro-*N*-phenylacetamide (0.187 g, 1.1 mmol) was added toluene (0.5 mL). The resulting solution was stirred for 1 hour at 100 °C and brought to rt. Diethyl ether (5 mL) was added and the mixture was filtered. The crude solid was washed with diethyl ether (2 X 5 mL) and dried under vacuum.

4. Synthesis of palladacycle [Pd(CAC:)(PPh₃)Cl].

Method A: To an acetonitrile solution (20 mL) of the imidazolium salt **ImidHCl** (0.400 g, 1.0 mmol) was added tetrakis(triphenylphosphine)palladium(0) [Pd(PPh₃)₄] (1.155 g, 1.0 mmol,) and stirred the mixture for 4 h at 50 °C. Then the reaction mixture was allowed to cool to room temperature before adding 4-dimethylaminopyridine (DMAP) (0.122 g, 1.0 mmol) and stirred for 2 h. The resultant mixture was filtered and the precipitate was washed with diethyl ether (2 X 5 mL). The crude product was dissolved in hot acetonitrile and kept at room temperature to obtain pale yellow crystals of [Pd(C Λ C:)PPh₃Cl]. Yield: 83% (0.608 g).

Method B: Same procedure as method A, except that [Pd₂(dba)₃] and PPh₃ were used instead of [Pd(PPh₃)₄]. [Pd₂(dba)₃] (0.457 g, 0.5 mmol), PPh₃ (0.262 g, 1.0 mmol), acetonitrile (20 mL), **ImidHCl** (0.400 g, 1.0 mmol), DMAP (0.122 g, 1.0 mmol) was added and stirred for 2 h. Yield: 80% (0.586 g).

5. General Procedure for the Synthesis of Substrates 1a - r



The methodology was adopted from the literature.¹⁴⁻¹⁵ The corresponding 2-bromobenzamide **S1** (4.0 mmol) was dissolved in dry DMF (5 mL) and cooled to 0 °C. A 60% dispersion of NaH in mineral oil (16.0 mmol) was added portion wise and stirred for 10 min. The mixture was allowed to come to room temperature and stirred for further 30 min. The mixture was cooled again to 0 °C and 2-methylallyl chloride (5.2 mmol) was added dropwise and stirred for 10 min before warming it up to room temperature. The mixture was stirred for 12 h before adding a mixture of water (100 mL) and EtOAc (20 mL). Organic layer was separated, washed with water (3 X 10 mL) and brine solution, dried over Na₂SO₄, filtered, and the volatiles were

removed under vacuum. The residue was purified by using silica gel column with a mixture of hexane/EtOAc as the eluent to obtain pure **1a-r**.





The methodology was adopted from the literature.⁸ The corresponding 2-bromo-Nallylbenzamide **S2** (4.0 mmol) was dissolved in dry DMF (5 mL) and cooled to 0 °C. A 60% dispersion of NaH in mineral oil (16.0 mmol) was added portion wise and stirred for 10 min. The mixture was allowed to come to room temperature and stirred for further 30 min. The mixture was cooled again to 0 °C and methyl iodide (8.0 mmol) or 2-methylallyl chloride (5.2 mmol) was added dropwise and stirred for 10 min before warming it up to room temperature. The mixture was stirred for 12 h before adding a mixture of water (100 mL) and EtOAc (20 mL). Organic layer was separated, washed with water (3 X 10 mL) and brine solution, dried over Na₂SO₄, filtered, and the volatiles were removed under vacuum. The residue was purified by using silica gel column with a mixture of hexane/EtOAc as the eluent to obtain pure **1s-v** and **3a-c**.

5.2. General Procedure for the Synthesis of the Substrates 1aa, 1ab



R₇ = Me R₈ = H R₉ = Ph; **S3** R₇ = Ph R₈ = Ph R₉ = OMe; **S4**



The methodology was adopted from the literature.¹⁶ To a solution of corresponding acrylamide **S3** or **S4** (5.0 mmol) in benzene (10 mL) was added Et_3N (10.0 mmol) followed by DMAP (1.0 mmol) at room temperature. The mixture was cooled to 0 °C and a solution of 2-bromobenzoyl

chloride (6 mmol) was added dropwise and stirred for 10 min. It was allowed to coe to room temperature and refluxed for 12 h. The resultant mixture was concentrated and diluted with water and extracted with EtOAc (2 X 20 mL), washed with saturated NaHCO₃ solution, water, brine, dried over MgSO₄ and the volatiles were removed under vacuum. The residue was purified by using silica gel column with a mixture of hexane/EtOAc as the eluent to obtain pure **1aa** and **1ab**.

5.3. Synthesis of substrate 1ac



2-Bromo-N-phenylbenzamide **S1** (4.0 mmol) was dissolved in dry DMF (5 mL) and cooled to 0 °C. A 60% dispersion of NaH in mineral oil (16.0 mmol) was added portion wise and stirred for 10 min. the mixture was allowed to come to room temperature and stirred for further 30 min. The mixture was cooled again to 0 °C and cinnamyl chloride (5.2 mmol) was added dropwise. The resultant mixture was stirred for 10 min at this temperature before it was allowed to come room temperature and stirred for 12 h. The mixture was then treated with H₂O (100 mL) and EtOAc (20 mL). The organic layer was separated and washed with water (3 X 10 mL), brine solution, dried over Na₂SO₄, filtered and the volatiles were removed under vacuum. The residue was purified by using silica gel column with a mixture of hexane/EtOAc as the eluent to obtain pure **1ac**.

6. General Procedure for Heck/Borylation Reactions



An oven dried Schlenk tube (18 mm X 150 mm) containing a magnetic stir-bar was charged with **1** or **3** or **5** (0.5 mmol), K₂CO₃ (1.0 mmol) and [Pd(CAC:)(PPh₃)Cl] (1.0 mol%), and purged with nitrogen for 10 minutes. DCE/H₂O (5:1) (3 mL) and B₂(Pin)₂ (1.0 mmol) were added in sequence. The resultant mixture was gently refluxed at 90 °C for 6 h after which time the reaction mixture was brought to room temperature. The contents were filtered through a Celite bed, which was washed with ethyl acetate (10 mL) and the washing was collected in the same filtration flask. The filtrate was treated with water (10 mL) and the mixture was extracted with ethyl acetate (2 X 10 mL). The ethyl acetate portion was dried over Na₂SO₄, filtered and subjected to vacuum in order to remove the volatiles. The crude product was purified by column chromatography using a mixture of hexane/EtOAc as eluent on silica gel (100-200).

7. Synthesis of 7a



A mixture of **3a** (0.2 g, 0.5 mmol) in 4 mL 20% HCl (v/v) was stirred at 110 °C for 3 h. Once complete consumption of starting material **3a** as monitored by TLC, the reaction mixture was diluted with diethyl ether and water. Separate the two layers and the organic layer was washed with brine solution. Drying over Na₂SO₄ and filtered and concentrated in vaccum. The residue was purified by column silica gel chromatography with hexane/EtOAc as the eluent to provide the product with the 80% (0.125 g) yield of **7a**.

Synthesis of 7b



To a stirred solution of **3a** (0.2 g, 0.5 mmol) in tetrahydrofuran (1.5 mL) and 3M NaOH (0.8 mL) solution was added dropwise at 0 °C. Subsequently 30% H₂O₂ solution in water (0.4 mL) was added and stirred for 30 min at room temperature. The reaction mixture was diluted with

 H_2O and EtOAc. Separate the two layers and the organic layer was washed with H_2O (10 mL) and brine solution. Drying over Na₂SO₄ and filtered and concentrated in vacuum. The residue was purified by column silica gel chromatography with hexane/ EtOAc as the eluent to afford a white solid of **7b** with the high yield of 92% (0.130 g).

8. Characterization of the Compounds:

ImidHCl.

Light yellow solid (0.380 g, 95%). mp: 231 – 232 °C. ¹H NMR (400 MHz, DMSO): δ 11.39 (s, 1H), 10.04 (s, 1H), 8.39 (t, *J* = 1.7 Hz, 1H), 8.33 – 8.16 (m, 3H), 8.15 – 8.01 (m, 2H), 7.71 (d, *J* = 7.7 Hz, 2H), 7.34 (t, *J* = 7.9 Hz, 2H), 7.09 (t, *J* = 7.4 Hz, 1H), 5.61 (s, 2H) ppm. ¹³C NMR (100 MHz,



DMSO): δ 163.45, 141.48, 141.40, 140.11, 139.39, 138.57, 138.53, 133.33, 132.44, 128.87, 128.76, 128.01, 124.38, 123.78, 122.70, 119.20, 52.11, 40.14, 39.93, 39.73, 39.52, 39.31, 39.10, 38.89 ppm. HRMS (ESI): m/z calcd for C1₉H₁₆ClN₅O [M - Cl]⁺ 364.1043, found 364.0973. IR (KBr): $\tilde{v} = 3468$, 3164, 3136, 2974, 2895, 1621, 1539, 1488, 1463, 1441, 1387, 1314, 1262, 1227, 1193, 1100, 1073, 1039, 949, 872, 803, 760, 731, 664, 617, 594, 532, 429 cm⁻¹.

[Pd(CAC:)(PPh₃)Cl].

Light yellow solid. Yield: Method A (0.608 g, 83%) and Method B (0.586 g, 80%) mp: $214 - 215 \,^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): δ 10.39 (s, 1H), 7.82 - 7.71 (m, 9H), 7.64 -7.59 (m, 2H), 7.48 - 7.43 (m, 1H), 7.42 - 7.31 (m, 10H), 7.31 - 7.27 (m, 2H), 7.08 (t, *J* = 7.4 Hz, 1H), 6.96 (dd, *J* = 8.2, 0.9 Hz, 1H), 5.57 (s, 2H) ppm. ¹³C NMR (100 MHz,



CDCl₃): δ 177.97, 176.60, 164.92, 162.53, 152.25, 141.15, 138.13, 137.60, 135.18, 135.12, 135.01, 134.89, 131.95, 131.49, 130.60, 129.95, 129.71, 128.85, 128.23, 128.15, 127.98, 127.88, 127.80, 124.41, 119.89, 114.89, 77.48, 77.16, 76.84, 54.16 ppm. ³¹P NMR (162 MHz, CDCl₃): δ 33.61 ppm. HRMS (ESI): m/z calcd for C₃₇H₃₁ClN₅OPPd [M + H]⁺ 732.0911, found 732.0935. IR (KBr): $\tilde{v} = 3423$, 3161, 3119, 3040, 1674, 1609, 1482, 1415, 1321, 1283, 1257, 1233, 1162, 1108, 1064, 1031, 949, 876, 838, 790, 750, 652, 623, 597, 466 cm⁻¹. Anal. Calcd for C₃₇H₂₉ClNOPPd: C, 60.67; H, 3.99; N, 9.56. Found: C, 60.108; H, 3.959; N, 9.330.

2-Bromo-N-(2-methylallyl)-N-phenylbenzamide (1a).

White solid (1.10 g, 83%), mp: 71 – 72 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.39 (d, J = 7.8 Hz, 1H), 7.16 – 7.12 (m, 4H), 7.10 – 7.07 (m, 1H), 7.07 – 7.03 (m, 2H), 7.02 – 6.97 (m, 1H), 4.87 (d, J = 0.8 Hz, 2H), 4.53 (s, 2H), 1.87 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 168.72, 141.81, 140.46, 138.67, 132.76, 129.83, 128.88, 127.62, 127.35, 126.72, 119.97,

113.83, 77.48, 77.16, 76.84, 54.96, 20.60 ppm. HRMS (ESI): m/z calcd for C₁₇H₁₇BrNO [M + H]⁺ 330.0493, found 330.0492. IR (KBr): $\tilde{v} = 3064$, 2976, 2928, 1813, 1645, 1588, 1493, 1469, 1430, 1388, 1289, 1259, 1204, 1158, 1053, 1024, 902, 756 cm⁻¹.

2-Bromo-N-(4-methoxyphenyl)-N-(2-methylallyl)benzamide (1b).

Yellow oil (1.07 g, 74%). ¹H NMR (400 MHz, CDCl₃): δ 7.38 (dd, J = 7.9, 0.5 Hz, 1H), 7.10 – 7.03 (m, 4H), 7.01 – 6.97 (m, 1H), 6.67 – 6.63 (m, 2H), 4.85 (d, J = 7.6 Hz, 2H), 4.48 (s, 1.8H), 3.80 (s, 0.2H), 3.68 (s, 3H), 1.87 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.01, 158.38, 140.55, 138.91, 134.56, 132.75, 129.72, 128.84, 128.78, 126.80,

119.78, 114.39, 113.99, 77.48, 77.16, 76.84, 55.34, 55.18, 20.64 ppm. HRMS (ESI): m/z calcd for C₁₈H₁₉BrNO₂ [M + H]⁺ 360.0599, found 360.0595. IR (KBr): \tilde{v} =3494, 2926, 1650, 1511, 1465, 1433, 1391 1295, 1250, 1171, 1030, 952, 836, 769, 744 cm⁻¹.

2-Bromo-N-(2-methylallyl)-N-(p-tolyl)benzamide (1c).

Yellow oil (1.21 g, 88%). ¹H NMR (400 MHz, CDCl₃): δ 7.38 (d, J = 8.0 Hz, 1H), 7.07 – 6.97 (m, 5H), 6.93 (d, J = 8.1 Hz, 2H), 4.86 (d, J = 1.0 Hz, 2H), 4.50 (s, 2H), 2.19 (s, 3H), 1.86 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 168.81, 140.52, 139.13, 138.83, 137.12, 132.71, 129.71, 129.50, 128.84, 127.35, 126.72, 119.88, 113.75, 77.48, 77.16,

76.84, 55.00, 21.04, 20.59 ppm. HRMS (ESI): m/z calcd for C₁₈H₁₉BrNO [M + H]⁺ 344.0650, found 344.0646. IR (KBr): \tilde{v} =3068, 2922, 1728, 1654, 1512, 1469, 1430, 1385, 1295, 1250, 1164, 1050, 1026, 900, 824, 767, 744 cm⁻¹.

2-Bromo-N-(4-fluorophenyl)-N-(2-methylallyl)benzamide (1d).

White solid (1.25 g, 90%), mp: 98 – 99 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.38 (d, J = 8.1 Hz, 1H), 7.14 – 6.99 (m, 5H), 6.82 (t, J = 8.6 Hz, 2H), 4.85 (d, J = 14.8 Hz, 2H), 4.48 (s, 2H), 1.86 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 168.68, 162.49, 160.03, 140.26, 138.48, 137.69 (d, J = 3.3 Hz), 132.78, 129.95, 129.43 (d, J = 8.7 Hz), 128.73, 126.86, 119.70,

115.90, 115.67, 114.24, 77.48, 77.16, 76.84, 55.05, 20.54 ppm. ¹⁹F NMR (471 MHz, CDCl₃):





Br

Ö

1d



 δ -113.74 ppm. HRMS (ESI): m/z calcd for C₁₇H₁₆BrFNO [M + H]⁺ 348.0399, found 348.0393. IR (KBr): \tilde{v} =3062, 2921, 2854, 1640, 1590, 1506, 1465, 1427, 1387, 12926, 1206, 1156, 1054, 1025, 896, 844, 744 cm⁻¹.

2-Bromo-N-(4-chlorophenyl)-N-(2-methylallyl)benzamide (1e).

White solid (1.24 g, 85%), mp: 58 – 60 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.29 (d, J = 7.8 Hz, 2H), 7.05 – 6.90 (m, 6H), 4.77 (d, J = 9.3 Hz, 2H), 4.41 (s, 2H), 1.76 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 168.33, 140.16, 140.07, 138.24, 132.84, 132.70, 129.97, 128.92, 128.83, 128.67, 126.82, 119.62, 114.10, 77.48, 77.16, 76.84, 54.77, 20.39 ppm. HRMS 1e (ESI): m/z calcd for C₁₇H₁₆BrClNO [M + H]⁺ 364.0103, found 364.0121. IR (KBr): $\tilde{v} = 3068$, 2970, 2920, 1907, 1803, 1643, 1587, 1488, 1379, 1290, 1212, 1160, 1092, 1019, 958, 899, 836, 739 cm^{-1} .

2-Bromo-N-(4-bromophenyl)-N-(2-methylallyl)benzamide (1f).

Yellow oil (1.05g, 64%), ¹H NMR (400 MHz, CDCl₃): δ 7.55 – 7.23 (m, 2H), 7.20 (d, J = 8.6 Hz, 2H), 7.06 – 6.91 (m, 5H), 4.79 (d, J = 13.5 Hz, 2H), 4.43 (s, 0.8H), 3.95 (d, J = 13.0 Hz, 0.2H), 1.78 (s, 3H) ppm.¹³C NMR (100 MHz, CDCl₃): δ 168.46, 140.81, 140.20, 138.33, 132.90, 132.07, 130.15, 129.27, 128.80, 126.99, 121.05, 119.80, 114.25, 77.48, 77.16, 76.84, 54.89, 20.54 ppm. HRMS (ESI): m/z calcd for $C_{17}H_{16}Br_2NO$ [M +

H]⁺ 409.9578, found 409.9565. IR (KBr): $\tilde{v} = 3438.38$, 3072.47, 2971.97, 2917.91, 1654.34, 1586.93, 1489.45, 1471.08, 1432.20, 1407.84, 1378.95, 1291.24, 1257.94, 1161.73, 1072.36, 1055.92, 1045.24, 1027.47, 1011.77, 902.90, 833.53, 768.89, 741.72, 611.73, 525.91 cm⁻¹.

2-Bromo-N-(2-methylallyl)-N-(naphthalen-1-yl)benzamide (1g).

White solid (0.988 g, 65%), mp: 62 - 65 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.02 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 8.2 Hz, 1H), 7.63 (dd, J = 11.6, 4.5 Hz, 2H), 7.54 - 7.49 (m, 1H), 7.45 (d, J = 7.2 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.24 – 7.19 (m, 1H), 6.85 (m, 2H), 6.71 (dt, *J* = 7.5, 3.8 Hz, 1H), 5.41 (d, *J* = 14.4 Hz, 1H), 4.85 (s, 1H), 4.76 (s, 1H), 3.78 (d, *J* = 14.4 Hz, 1H), 1.98 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.47, 140.51, 138.46,

137.38, 134.45, 132.64, 129.89, 129.78, 128.87, 128.84, 127.29, 127.01, 126.40, 126.35, 125.21, 122.64, 119.86, 114.71, 77.48, 77.16, 76.84, 54.50, 21.08 ppm. HRMS (ESI): m/z calcd for $C_{21}H_{19}BrNO [M + H]^+ 380.0650$, found 380.0642. IR (KBr): $\tilde{v} = 3061.67, 2928.13, 1651.87$, 1595.69, 1508.42, 1471.81, 1432.29, 1403.21, 1382.38 cm-1.

2-Bromo-N-(2-methylallyl)-N-(2-(prop-1-en-2-yl)phenyl)benzamide (1h).





CI



1g

This compound exists as a mixture of rotamers. Colorless oil (0.859 g, 58%). ¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, *J* = 8.0 Hz, 0.2H), 7.45 (d, *J* = 3.7 Hz, 0.7H), 7.36 – 7.20 (m, 1.9H), 7.12 (dd, *J* = 7.7, 2.0 Hz, 1.3H), 7.06 (td, *J* = 7.5, 1.2 Hz, 0.8H), 7.01 – 6.91 (m, 3H), 5.31 – 5.27 (m, 0.7H), 5.23 (d, *J* = 20.4 Hz, 0.7H), 5.16 (d, *J* = 8.7 Hz, 0.7H), 5.04 (s, 0.7H), 4.83



1h

(d, J = 9.5 Hz, 1.5H), 4.65 (s, 0.3H), 4.53 (s, 0.2H), 3.95 (d, J = 47.3 Hz, 0.5H), 3.71 (d, J = 14.8 Hz, 0.7H), 2.10 (2s, 3H), 1.85 (s, 2H), 1.75 (s, 0.4H), 1.59 (s, 0.6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 168.29, 142.91, 141.37, 140.70, 139.00, 138.59, 137.91, 133.27, 130.38, 129.89, 129.83, 129.56, 128.14, 127.75, 127.64, 127.32, 126.44, 121.41, 117.84, 113.94, 77.48, 77.16, 76.84, 53.54, 23.41, 21.02 ppm. HRMS (ESI): m/z calcd for C₂₀H₂₁BrNO [M + H]⁺ 370.0806, found 370.0882. IR (KBr): $\tilde{v} = 3074$, 2972, 1811, 1654, 1593, 1487, 1436, 1378, 1296, 1249, 1216, 1161, 1028, 949, 902, 768, 742 cm⁻¹.

2-Bromo-N-methyl-N-(2-methylallyl)benzamide (1i).

This compound exists as a mixture of rotamers. Colorless oil (0.707 g, 66%). ¹H NMR (400 MHz, CDCl₃): δ 7.52 – 7.48 (m, 1H), 7.33 – 7.24 (m, 1H), 7.22 – 7.15 (m, 2H), 4.92 – 4.89 (m, 1H), 4.87 – 4.84 (m, 0.5H), 4.80 (s, 0.5H), 4.19 (d, *J* = 13.9 Hz, 0.5H), 3.98 (d, *J* = 13.8 Hz, 0.5H), 3.65 (d, *J* = 15.8 Hz, 0.5H), 3.55 (d, *J* = 15.7 Hz, 0.5H), 3.00 (1s, 1.4H), 2.69 (1s, 1.6H),



1.76 (1s, 1.6H), 1.52 (1s, 1.4H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.56, 169.12, 140.07, 139.84, 138.58, 138.01, 132.74, 132.66, 130.19, 130.11, 127.80, 127.71, 127.62, 127.43, 119.23, 118.81, 113.22, 113.20, 77.48, 77.16, 76.84, 56.52, 52.32, 35.32, 32.10, 20.14, 19.82 ppm. HRMS (ESI): m/z calcd for C₁₂H₁₅BrNO [M + H]⁺ 268.0337, found 268.0333. IR (KBr): $\tilde{v} = 2977, 1716, 1645, 1435, 1398, 1285, 1173, 1082, 1029, 903, 767 \text{ cm}^{-1}$.

2-Bromo-N-butyl-N-(2-methylallyl)benzamide (1j).

This compound exists as a mixture of rotamers. Yellow oil (0.881 g, 71%). ¹H NMR (400 MHz, CDCl₃): δ 7.55 (m, 1H), 7.37 – 7.27 (m, 1H), 7.26 – 7.17 (m, 2H), 4.97 (d, *J* = 10.1 Hz, 1H), 4.88 (dd, *J* = 10.9, 9.6 Hz, 1.2H), 4.47 (d, *J* = 15.0 Hz, 0.4H), 3.97 – 3.88 (m, 0.6H), 3.85 (d, *J* = 15.1 Hz, 0.5H), 3.64 (s, 1H), 3.08 – 2.95 (m, 1.5H), 1.82 (s, 1.4H), 1.55 (s, 2H),



1.47 - 1.30 (m, 2H), 1.13 - 1.04 (m, 1H), 0.96 (t, J = 7.3 Hz, 1.8H), 0.73 (t, J = 7.4 Hz, 1.4H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.04, 168.99, 140.41, 140.11, 138.51, 138.22, 132.67, 132.48, 129.94, 127.78, 127.69, 127.31, 119.07, 118.90, 113.24, 112.85, 77.48, 77.16, 76.84, 54.03, 49.05, 46.88, 43.98, 29.72, 28.70, 20.30, 20.23, 19.85, 19.62, 13.77, 13.37 ppm. HRMS

(ESI): m/z calcd for C₁₅H₂₁BrNO [M + H]⁺ 310.0806, found 310.0796. IR (KBr): $\tilde{v} = 3076$, 2961, 2931, 2868, 1641, 1425, 1289, 1243, 1162, 1107, 1028, 954, 900, 770, 746 cm⁻¹.

2-Bromo-N-cyclohexyl-N-(2-methylallyl)benzamide (1k).

This compound exists as a mixture of rotamers. Yellow oil (0.928 g, 69%). ¹H NMR (400 MHz, CDCl₃): δ 7.54 – 7.40 (m, 1H), 7.31 – 7.07 (m, 3H), 4.98 (d, J = 0.4 Hz, 0.5H), 4.86 – 4.79 (m, 1H), 4.76 (d, J = 1.3 Hz, 0.4H), 4.36 – 4.29 (m, 0.4H), 4.13 – 4.01 (m, 0.6H), 3.88 (d, J = 16.2 Hz, 0.5H), 3.58 (d, J = 17.1 Hz, 0.5H), 3.44 (d, J = 16.9 Hz, 0.4H), 3.21 – 3.14 (m, **1**k

0.5H), 1.89 (d, J = 11.1 Hz, 1.5H), 1.77 (s, 1.7H), 1.72 (s, 0.5H), 1.69 – 1.49 (m, 3H), 1.42 (d, J = 7.1 Hz, 3H), 1.39 – 1.33 (m, 1H), 1.10 – 0.76 (m, 2.7H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.69, 169.14, 142.08, 141.95, 139.11, 138.77, 132.83, 132.28, 129.84, 129.80, 128.14, 127.49, 127.33, 127.12, 118.98, 118.91, 112.06, 110.85, 77.48, 77.16, 76.84, 59.30, 54.99, 50.69, 46.49, 31.49, 31.26, 25.74, 25.57, 25.52, 25.04, 20.76, 20.24 ppm. HRMS (ESI): m/z calcd for C₁₇H₂₃BrNO [M + H]⁺ 336.0963, found 336.0952. IR (KBr): $\tilde{v} = 3846.31$, 3664.55, 3439.47, 3075.53, 3048.42, 2945.57, 2856.95, 2670.39, 2431.96, 2241.07, 1960.85, 1925.18, 1807.49, 1720.58, 1643.97, 1565.38, 1416.12, 1374.41 cm^{-1.}

2-Bromo-N-(tert-butyl)-N-(2-methylallyl)benzamide (11).

Colorless oil (0.955 g, 77%). ¹H NMR (400 MHz, CDCl₃): δ 7.50 – 7.45 (m, 1H), 7.26 – 7.21 (m, 2H), 7.16 – 7.10 (m, 1H), 5.00 (s, 1H), 4.91 (d, *J* = 1.2 Hz, 1H), 3.78 (d, *J* = 18.8 Hz, 1H), 3.49 (d, *J* = 18.7 Hz, 1H), 1.56 (s, 9H), 1.45 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 170.36, 143.41, 140.30, 132.41, 129.54, 127.46, 127.20, 118.84, 111.28, 77.48, 77.16, 76.84, 58.33,



52.19, 28.36, 20.25 ppm. HRMS (ESI): m/z calcd for C15H21BrNO [M + H]+ 310.0806, found 310.0796. IR (KBr): $\tilde{v} = 3064$, 2917, 1640, 1437, 1392, 1365, 1275, 1239, 1199, 1166, 1129, 1028, 949, 895,768, 746 cm⁻¹.

N-Benzyl-2-bromo-N-(2-methylallyl)benzamide (1m).

This compound exists as a mixture of rotamers. Colorless oil (1.14 g, 83%). ¹H NMR (400 MHz, CDCl₃): δ 7.60 – 7.53 (m, 1H), 7.46 – 7.42 (m, 1H), 7.37 – 7.27 (m, 5H), 7.23 – 7.18 (m, 1H), 7.17 – 7.10 (m, 1H), 5.39 (d, J = 14.4 Hz, 0.5H), 4.96 (dd, J = 6.4, 5.2 Hz, 1H), 4.87 (d, J = 18.3 Hz, 1H), 4.61 (d, J = 14.9 Hz, 0.4H), 4.43 – 4.25 (m, 1H), 4.15 (d, J = 14.4 Hz, 0.6H), 3.61 (d, J = 15.0 Hz, 0.5H), 3.56 (d, J = 4.5 Hz, 1H), 1.86 (s, 1.2H), 1.56 (s,



1.8H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.82, 169.57, 140.03, 139.77, 138.32, 138.02, 136.63, 136.06, 133.03, 132.90, 130.33, 130.31, 129.07, 128.79, 128.56, 128.24, 128.06,

127.78, 127.68, 127.64, 127.50, 127.43, 119.42, 119.35, 114.09, 113.59, 77.48, 77.16, 76.84, 53.00, 50.80, 48.84, 46.72, 20.74, 20.14 ppm. HRMS (ESI): m/z calcd for C₁₈H₁₉BrNO [M + H]+ 344.0650, found 344.1158. IR (KBr): $\tilde{v} = 3054.03$, 2753.20, 2629.92, 2479.92, 2363.41, 2193.83, 1530.62, 1321.06, 1350.75 cm⁻¹.

2-Bromo-5-methoxy-N-methyl-N-(2-methylallyl)benzamide (1n).

This compound exists as a mixture of rotamers. Colorless oil (1.03 g, 56%).¹H NMR (400 MHz, CDCl₃): δ 7.43 – 7.38 (m, 1H), 6.78 – 6.73 (m, 2H), 4.93 (dd, J = 2.5, 1.2 Hz, 1H), 4.88 (dd, J = 13.3, 12.1 Hz, 1H), 4.23 (d, J = 14.4 Hz, 0.5H), 3.97 (d, J = 14.5 Hz, 0.5H), 3.76 (s, 1.5H), 3.73 (s, 1.5H), 3.71 – 3.67 (m, 0.4H), 3.57 (dd, J = 14.5, 7.0 Hz, 0.5H), 3.01 (s,



1.4H), 2.74 (s, 1.6H), 1.78 (s, 1.6H), 1.57 (s, 1.4H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.47, 169.04, 159.19, 158.92, 140.18, 140.04, 139.36, 138.78, 133.68, 133.56, 116.53, 116.38, 113.35, 113.30, 113.26, 113.03, 109.53, 109.17, 77.48, 77.16, 76.84, 56.62, 55.66, 55.62, 52.46, 35.38, 32.17, 20.26, 19.98 ppm. HRMS (ESI): m/z calcd for C₁₃H₁₇BrNO₂ [M + H]+ 298.0000, found 298.0435. IR (KBr): $\tilde{v} = 3077, 2940, 1643, 1594, 1571, 1465, 1405, 1288,$ 1237, 1086, 1042, 1017, 900, 816 cm⁻¹.

2-Bromo-4,5-dimethoxy-N-methyl-N-(2-methylallyl)benzamide (10).

This compound exists as a mixture of rotamers. Yellow oil (1.09 g, 83%). ¹H NMR (400 MHz, CDCl₃): δ 6.93 – 6.85 (m, 1H), 6.70 – 6.61 (m, 1H), 4.83 (s, 1H), 4.77 (d, J = 21.3 Hz, 1H), 4.32 – 3.86 (m, 1H), 3.78 – 3.72 (m, 4.7H), 3.69 (d, J = 1.3 Hz, 1.5H), 3.65 – 3.43 (m, 1H), 2.92 (d, J = 1.3 Hz, 1.5H), 2.67 (d, J = 1.3 Hz, 1.5H), 1.69 (s, 1.5H),



Br

F₃C

С

1p

1.47 (s, 1.5H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.40, 168.96, 149.60, 149.55, 148.54, 148.18, 139.98, 139.94, 130.24, 129.60, 115.02, 115.00, 113.04, 112.79, 110.30, 110.04, 109.47, 109.05, 77.48, 77.16, 76.84, 56.47, 56.02, 55.93, 55.86, 52.30, 35.24, 32.11, 20.07, 19.76 ppm. HRMS (ESI): m/z calcd for C₁₄H₁₉BrNO₃ [M + H]⁺ 328.0548, found 328.0542. IR (KBr): $\tilde{v} = 3480$, 2936, 2842, 1640, 1601, 1506, 1440, 1401, 1369, 1331, 1259, 1211, 1160, 1089, 1029, 858, 794 cm⁻¹.

2-Bromo-N-methyl-N-(2-methylallyl)-4-(trifluoromethyl)benzamide (1p).

This compound exists as a mixture of rotamers. White solid (1.02 g, 76%), mp: 50 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.83 (d, *J* = 7.1

Hz, 1H), 7.64 - 7.55 (m, 1H), 7.37 (d, J = 7.8 Hz, 1H), 4.95 (dd, J

= 9.8, 0.6 Hz, 1H), 4.93 - 4.82 (m, 1H), 4.26 (d, J = 14.5 Hz, 0.5H),

4.00 (d, J = 14.4 Hz, 0.5H), 3.68 – 3.55 (m, 1H), 3.05 (s, 1.4H), 2.73 (s, 1.6H), 1.79 (s, 1.5H),

1.56 (s, 1.5H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 168.41, 168.02, 142.30, 141.76, 139.88, 139.59, 132.57 (d, J = 4.3 Hz), 132.26, 129.92, 128.29, 124.96 – 124.91 (m), 124.71 (d, J = 29.1 Hz), 124.23, 121.52, 119.65 (d, J = 41.9 Hz), 113.60 (d, J = 21.2 Hz), 77.48, 77.00 (d, J = 32.0 Hz), 56.54, 52.55, 35.33, 32.40, 20.24, 19.95 ppm. ¹⁹F NMR (471 MHz, CDCl₃): δ - 62.98, -62.99 ppm. HRMS (ESI): m/z calcd for C₁₃H₁₄BrF₃NO [M + H]⁺ 336.0210, found 336.0197. IR (KBr): $\tilde{v} = 3089$, 2969, 2913, 1643, 1562, 1502, 1436, 1455, 1391, 1326, 1285, 1251, 1171, 1128, 1076, 1033, 910, 885, 856, 750, 706 cm⁻¹.

2-Bromo-4-fluoro-N-methyl-N-(2-methylallyl)benzamide (1q).

This compound exists as a mixture of rotamers. Yellow oil (0.972 g, 85%). ¹H NMR (400 MHz, CDCl₃): δ 7.26 – 7.21 (m, 1H), 7.19 – 7.15 (m, 1H), 7.03 – 6.94 (m, 1H), 4.91 – 4.81 (m, 1.6H), 4.76 (s, 0.5H), F 4.05 (d, J = 80.8 Hz, 1H), 3.56 (q, J = 15.3 Hz, 1H), 2.97 (s, 1.5H),



2.67 (s, 1.5H), 1.72 (s, 1.5H), 1.49 (s, 1.5H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 168.96, 168.53, 163.47 (d, J = 4.5 Hz), 160.96 (d, J = 4.4 Hz), 139.98, 139.76, 134.88 (d, J = 3.7 Hz), 134.29 (d, J = 3.8 Hz), 129.36 – 128.80 (m), 120.51 – 119.75 (m), 119.47 (d, J = 9.6 Hz), 115.33, 115.07 (d, J = 7.4 Hz), 114.82, 113.30 (d, J = 15.3 Hz), 77.48, 77.16, 76.84, 56.63, 52.53, 35.45, 32.43, 20.19, 19.89 ppm. ¹⁹F NMR (471 MHz, CDCl₃): δ -109.75, -109.94 ppm. HRMS (ESI): m/z calcd for C₁₂H₁₄BrFNO [M + H]⁺ 286.0242, found 286.0233. IR (KBr): $\tilde{v} = 3668.61, 3470.33, 3080.40, 3046.54, 2964.81, 2732.52, 2546.02, 2462.15, 2327.01, 2077.10, 1890.46, 1636.10, 1420.30, 1341.53 cm⁻¹.$

2-Bromo-5-chloro-N-methyl-N-(2-methylallyl)benzamide (1r).

This compound exists as a mixture of rotamers. White solid (0.968 g, 80%), mp: 64 – 66 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.48 (dd, J = 7.9, 6.6 Hz, 1H), 7.25 – 7.16 (m, 2H), 4.96 (s, 0.6H), 4.93 (s, 1H), 4.84 (s, 0.4H), 4.22 (d, J = 14.1 Hz, 0.5H), 4.00 (d, J = 14.3 Hz, 0.5H), 3.74 –



3.54 (m, 1H), 3.03 (s, 1.3H), 2.75 (s, 1.7H), 1.79 (s, 1.7H), 1.59 (s, 1.3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 168.26, 167.85, 140.13, 139.97, 139.71, 139.58, 134.14, 134.08, 134.05, 133.84, 130.44, 130.37, 128.00, 127.84, 117.36, 116.95, 113.61, 77.48, 77.16, 76.84, 56.66, 52.57, 35.42, 32.37, 20.27, 19.99 ppm. HRMS (ESI): m/z calcd for C₁₂H₁₄BrClNO [M + H]⁺ 301.9947, found 301.9937. IR (KBr): $\tilde{v} = 3090.39$, 3057.12, 2925.59, 2853.66, 1676.74, 1639.55, 1583.43, 1496.52, 1476.23, 1453.51, 1429.41, 1336.63, 1253.78, 1240.69 cm-1.

2-Bromo-N-methyl-N-(2-phenylallyl)benzamide (1s).

This compound exists as a mixture of rotamers. White solid (0.766

g, 58%), mp: 145 – 147 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.49 – 7.44 (m, 1.7H), 7.41 (d, J = 8.0 Hz, 0.7H), 7.31 – 7.14 (m, 5H), 7.14 – 7.00 (m, 2H), 6.92 (d, J = 7.5 Hz, 0.7H), 5.46 (s, 0.7H), 5.33 (s, 0.3H), 5.25 (s, 0.7H), 5.13 (s, 0.3H), 4.72 (d, J = 14.9 Hz, 0.7H),



4.52 (d, J = 14.8 Hz, 0.7H), 4.15 (d, J = 16.4 Hz, 0.3H), 3.97 (d, J = 16.4 Hz, 0.3H), 3.02 (d, J = 0.5 Hz, 1H), 2.58 (d, J = 0.6 Hz, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.62, 169.00, 143.39, 143.20, 138.59, 138.36, 138.09, 137.76, 132.63, 132.58, 130.34, 130.05, 128.38, 128.09, 128.05, 127.91, 127.57, 127.46, 127.37, 126.46, 126.17, 119.23, 118.73, 115.37, 114.72, 77.48, 77.16, 76.84, 54.47, 49.77, 34.95, 32.56 ppm. HRMS (ESI): m/z calcd for C₁₇H₁₇BrNO [M + H]⁺ 330.0493, found 330.0492. IR (KBr): $\tilde{v} = 3855$, 3759, 3052, 2924, 2331, 1642, 1490, 1447, 1399, 1277, 1168, 1079, 1030, 980, 909, 773, 746, 705 cm⁻¹.

2-Bromo-N-methyl-N-(2-(p-tolyl)allyl)benzamide (1t).

This compound exists as a mixture of rotamers. Yellow oil (0.895 g, 65%). ¹H NMR (400 MHz, CDCl₃): δ 7.54 (d, *J* = 7.6 Hz, 0.3H), 7.49 (d, *J* = 8.0 Hz, 0.6H), 7.41 (d, *J* = 8.1 Hz, 1.3H), 7.29 – 7.13 (m, 4H), 7.07 (d, *J* = 8.0 Hz, 0.7H), 7.02 – 6.98 (m, 1.3H), 5.50 (s,



0.6H), 5.38 (s, 0.3H), 5.26 (s, 0.6H), 5.14 (s, 0.3H), 4.80 (d, J = 15.0 Hz, 0.6H), 4.52 (d, J = 15.0 Hz, 0.6H), 4.20 (d, J = 16.4 Hz, 0.3H), 4.02 (d, J = 16.4 Hz, 0.3H), 3.08 (s, 1H), 2.65 (s, 2H), 2.32, 2.29 (2s, 3.2H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.74, 169.10, 143.13, 143.03, 138.51, 138.05, 137.92, 135.72, 135.27, 132.73, 132.66, 130.39, 130.11, 129.15, 128.00, 127.65, 127.59, 127.44, 126.36, 126.08, 119.34, 118.86, 114.57, 113.96, 77.48, 77.16, 76.84, 54.50, 49.89, 35.02, 32.65, 21.20, 21.14 ppm. HRMS (ESI): m/z calcd for C₁₈H₁₉BrNO [M + H]⁺ 344.0650, found 344.0640. IR (KBr): $\tilde{\nu} = 3084$, 3054, 3022, 2922, 2865, 1654, 1565, 1509, 1488, 1449, 1398, 1277, 1079, 1030, 904, 826, 769, 740 cm⁻¹.

2-Bromo-N-(2-(4-fluorophenyl)allyl)-N-methylbenzamide (1u).

This compound exists as a mixture of rotamers. Yellow oil (0.849 g, 61%). ¹H NMR (400 MHz, CDCl₃): δ 7.55 – 7.45 (m, 2.6H), 7.29 – 7.11 (m, 3H), 7.07 – 6.90 (m, 3.8H), 5.47 (s, 0.7H), 5.34 (s, 0.3H), 5.29 (s, 0.7H), 5.17 (s, 0.3H), 4.69 (d, *J* = 13.4 Hz,



0.7H), 4.59 (d, J = 13.8 Hz, 0.7H), 4.16 (d, J = 16.4 Hz, 0.3H), 4.00 (d, J = 16.3 Hz, 0.3H), 3.07 (s, 1H), 2.64 (s, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.62, 169.07, 163.85 (d, J = 12.7 Hz), 161.39 (d, J = 13.1 Hz), 219.44 – 130.05 (m), 142.43 (d, J = 17.6 Hz), 138.32, 137.78, 134.76 (d, J = 3.1 Hz), 134.46 (dd, J = 58.8, 3.1 Hz), 137.53 – 130.53 (m), 128.30 (d, J = 8.0 Hz), 128.10 – 127.82 (m), 127.76 – 127.24 (m), 119.33, 118.74, 115.29 (dt, J = 24.2, 12.9 Hz), 77.48, 77.16, 76.84, 54.60, 49.87, 34.91, 32.57 ppm. ¹⁹F NMR (471 MHz, CDCl₃): δ -113.68, -114.03, -115.92, -115.96, -116.47, -116.51 ppm. HRMS (ESI): m/z calcd for C₁₇H₁₆BrFNO [M + H]⁺ 348.0399, found 348.0396. IR (KBr): $\tilde{\nu} = 3063, 2965, 2927, 1598, 1508, 1453, 1400,$ 1226, 1080, 1031, 839, 770, 744 cm⁻¹.

2-Bromo-N-(2-(4-chlorophenyl)allyl)-N-methylbenzamide (1v).

This compound exists as a mixture of rotamers. Yellow oil (0.670 g, 46%). ¹H NMR (400 MHz, CDCl₃) δ 7.57 (dd, *J* = 8.0, 1.0 Hz, 0.3H), 7.53 – 7.46 (m, 2.3H), 7.35 – 7.14 (m, 5H), 7.06 – 7.01 (m, 1.3H), 5.54 (s, 0.7H), 5.41 (s, 0.3H), 5.35 (s, 0.7H), 5.23 (s, 0.3H), 4.67 (q, *J* = 14.7 Hz, 1.6H), 4.20 (d, *J* = 16.4 Hz, 0.3H),



4.03 (d, J = 16.5 Hz, 0.3H), 3.09 (s, 0.9H), 2.66 (s, 2.1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.77, 169.23, 142.53, 142.34, 138.33, 137.80, 137.15, 136.59, 134.15, 134.07, 132.85, 130.57, 130.29, 128.72, 128.68, 128.05, 127.99, 127.78, 127.65, 127.63, 127.55, 119.44, 118.86, 116.23, 115.52, 77.48, 77.16, 76.84, 54.50, 49.84, 35.04, 32.72 ppm. HRMS (ESI): m/z calcd for C₁₇H₁₆BrClNO [M + H]⁺ 364.0103, found 364.0110. IR (KBr): $\tilde{v} = 2923$, 1722, 1641, 1490, 1432, 1399, 1277, 1083, 1031, 910, 835, 768, 744 cm⁻¹.

2-Bromo-N-methacryloyl-N-phenylbenzamide (1aa).

White solid (1.20 g, 70%), mp: 60 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.45 (d, *J* = 7.9 Hz, 1H), 7.38 – 7.33 (m, 1H), 7.29 (q, *J* = 7.3 Hz, 2H), 7.22 (t, *J* = 7.5 Hz, 2H), 7.18 (d, *J* = 8.1 Hz, 2H), 7.13 (td, *J* = 7.9, 1.3 Hz, 1H), 5.68 (s, 1H), 5.36 (s, 1H), 1.67 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 173.82, 170.70, 141.30, 138.49, 137.86, 134.69, 133.45, 133.35, 132.21,



131.44, 129.44, 129.36, 128.26, 127.82, 127.26, 123.74, 122.29, 119.94, 77.48, 77.16, 76.84, 18.56 ppm. HRMS (ESI): m/z calcd for C₁₇H₁₅BrNO₂ [M + H]⁺ 344.0286, found 344.0279. IR (KBr): $\tilde{v} = 3325$, 3199, 3064, 2981, 2924, 2853, 1710, 1594, 1536, 1494, 1436, 1290, 1166, 1030, 917, 749, 603 cm⁻¹.

(Z)-2-Bromo-N-(2,3-diphenylacryloyl)-N-methoxybenzamide (1ab).

White solid (1.88 g, 86%), mp: 61 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.04 – 7.99 (m, 1H), 7.77 – 7.73 (m, 1H), 7.45 – 7.40 (m, 2H), 7.40 – 7.36 (m, 5H), 7.28 (s, 1H), 7.16 – 7.10 (m, 3H), 7.01 – 6.97 (m, 2H), 3.87 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 161.03, 150.30, 135.43, 135.31, 134.81, 133.61, 133.18, 132.27, 131.79, 130.32, 130.23, 129.99, 128.64, 128.18, 128.12, 128.04, 127.41, 122.66, 77.48,



77.16, 76.84, 63.08 ppm. HRMS (ESI): m/z calcd for $C_{23}H_{19}BrNO_3 [M + H]^+ 436.0548$, found 436.0536. IR (KBr): $\tilde{v} = 2938$, 1757, 1635, 1584, 1491, 1466, 1437, 1263, 1288, 1229, 1158, 1129, 1076, 1045, 1018, 963, 910, 778, 738, 706 cm⁻¹.

2-Bromo-N-cinnamyl-N-phenylbenzamide (1ac).

Yellow oil (1.02 g, 65%). ¹H NMR (400 MHz, CDCl₃): δ 7.32 - 7.28 (m, 3H), 7.23 (d, J = 7.7 Hz, 2H), 7.19 - 7.17 (m, 1H), 7.13 - 7.06 (m, 4H), 7.06 - 6.98 (m, 3H), 6.93 (td, J = 7.7, 2.1 Hz, 1H), 6.47 (d, J = 15.9 Hz, 1H), 6.35 (dt, J = 15.9, 6.5 Hz, 1H), 4.62 (d, J = 6.3 Hz, 2H) ppm. ¹³C NMR (101 MHz, CDCl₃)

δ 168.52, 141.76, 138.46, 136.73, 133.70, 132.68, 129.88, 128.99, 128.87, 128.63, 128.02, 127.81, 127.60, 126.73, 126.58, 123.98, 119.77, 77.48, 77.16, 76.84, 51.85 ppm. HRMS (ESI): m/z calcd for C₂₂H₁₉BrNO [M + H]⁺ 392.0650, found 392.0644 IR (KBr): $\tilde{v} = 2977.91$, 2928.10, 2857.69, 2551.30, 2333.64, 1951.90, 1881.00, 1805.94, 1276.47, 1263.87, 1250.10, 1250.37, 1157.72, 1122.02, 1076.23, 1026.79 cm-1.

N-Allyl-2-bromo-N-methylbenzamide (3a).

This compound exists as a mixture of rotamers. Colorless oil (0.813 g, 80%). ¹H NMR (400 MHz, CDCl₃): δ 7.49 (dd, J = 7.5, 1.0 Hz, 1H), 7.31 – 7.13 (m, 3H), 5.87 – 5.76 (m, 0.5H), 5.66 – 5.57 (m, 0.5H), 5.25 – 5.17 (m, 1H), 5.14 – 5.04 (m, 1H), 4.22 (s, 0.5H), 4.01 (s, 0.5H), 3.71 – 3.57 **3a**

(m, 1H), 3.01 (s, 1.5H), 2.71 (s, 1.5H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.37, 169.03, 138.56, 138.29, 132.85, 132.83, 132.65, 132.37, 130.31, 130.26, 127.83, 127.72, 127.70, 127.60, 119.23, 119.05, 118.17, 118.12, 77.48, 77.16, 76.84, 53.47, 49.50, 35.61, 32.26 ppm. HRMS (ESI): m/z calcd for C₁₁H₁₃BrNO [M + H]⁺ 254.0180, found 254.0174. IR (KBr): $\tilde{v} =$ 3076, 2924, 1637, 1591, 1487, 1426, 1400, 1289, 1252, 1117, 1079, 1030, 994, 926, 771, 748, 688 cm⁻¹.

N-Allyl-2-bromo-N-(2-methylallyl)benzamide (3b).

This compound exists as a mixture of rotamers. Colorless oil (0.706 g, 60%). ¹H NMR (400 MHz, CDCl₃): δ 7.49 (t, J = 7.5 Hz, 1H), 7.31 – 7.12 (m, 3.2H), 5.96 – 5.78 (m, 0.5H), 5.62 – 5.52 (m, 0.5H), 5.29 – 4.77 (m, 4.5H), 4.62 (d, J = 14.4 Hz, 0.5H), 4.45 (d, J = 14.9 Hz, 0.5H), 3.76 – 3.50 (m, 3.2H), 1.76 (s, 1.5H), 1.49 (s, 1.5H) ppm. ¹³C NMR (100 MHz, CDCl₃): **3b** δ 169.38, 169.31, 140.16, 139.88, 138.35, 138.01, 132.92, 132.76, 132.47, 132.35, 130.29, 127.85, 127.81, 127.53, 119.31, 119.05, 118.38, 118.35, 113.53, 113.23, 77.48, 77.16, 76.84,

53.20, 49.87, 48.85, 46.39, 20.53, 20.10 ppm. HRMS (ESI): m/z calcd for C₁₄H₁₇BrNO [M +

H]⁺ 294.0493, found 294.0482. IR (KBr): $\tilde{v} = 3078$, 2977, 2919, 1640, 1592, 1416, 1340, 1291, 1246, 1159, 1116, 1027, 989, 908, 771, 751 cm⁻¹.

2-Bromo-N-(2-methylallyl)-N-(2-phenylallyl)benzamide (3c).

This compound exists as a mixture of multiple rotamers. Yellow oil (0.829 g, 56%).¹H NMR (400 MHz, CDCl₃): δ 7.51 – 6.80 (m, 9H), 5.43 (d, *J* = 0.6 Hz, 0.3H), 5.32 (d, *J* = 0.7 Hz, 0.2H), 5.26 (d, *J* = 1.1 Hz, 0.3H), 5.07 (dd, *J* = 12.92 Hz, 0.6H), 4.93 – 4.76 (m, 2H), 4.65 (d, *J* = 5.8 Hz, 0.2H), 4.14 (d, *J* = 15.3 Hz, 0.3H), 4.01 (s, 0.6H), 3.50 (t, *J* = 20.6 Hz, 1H), 3.39 – 3.01 (m, 1H), 1.85 – 1.67 (m, 1.6H), 1.46 (2s,



1.4H), 1.37 (s, 0.4H), 1.31 – 1.25 (m, 0.7H), 1.02 (dd, J = 23.6, 7.0 Hz, 0.3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 169.82, 169.54, 143.41, 143.09, 140.30, 139.63, 139.05, 138.81, 138.26, 137.91, 137.89, 132.88, 132.80, 130.39, 130.22, 130.15, 128.72, 128.50, 128.16, 128.10, 127.70, 127.56, 127.35, 127.29, 126.86, 126.70, 126.30, 119.18, 119.12, 115.98, 114.17, 113.98, 113.31, 77.48, 77.16, 76.84, 52.70, 50.69, 49.31, 46.43, 20.77, 20.22 ppm. HRMS (ESI): m/z calcd for C₂₀H₂₁BrNO [M + H]⁺ 370.0806, found 370.0853. IR (KBr): $\tilde{v} = 3078$, 2969, 2923, 1642, 1423, 1279, 1244, 1156, 1099, 1025, 992, 944, 903, 772, 750, 703 cm⁻¹.

 $\label{eq:2-2-2-2} 4-Methyl-2-phenyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4-interval (1,2,2,3) + interval (1,2,3) + interva$

dihydroisoquinolin-1(2H)-one (2a).

White solid, (0.177 g, 94%), mp: 88 – 90 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.14 (dd, J = 7.7, 1.3 Hz, 1H), 7.50 – 7.44 (m, 1H), 7.44 – 7.38 (m, 4H), 7.37 (dd, J = 3.7, 1.3 Hz, 1H), 7.35 – 7.30 (m, 1H), 7.26 – 7.21 (m, 1H), 4.03 (d, J = 12.3 Hz, 1H), 3.77 (d, J = 12.3 Hz, 1H), 1.49 (s, 3H), 1.41 (d, J = 15.7 Hz, 1H), 1.33 (d, J = 15.7 Hz, 1H), 1.14 (s, 6H),



1.08 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.18, 147.95, 143.31, 132.25, 128.96, 128.89, 128.26, 126.69, 126.18, 125.56, 123.82, 83.25, 77.48, 77.16, 76.84, 60.67, 36.22, 25.87, 24.77, 24.71 ppm. HRMS (ESI): m/z calcd for C₂₃H₂₉BNO₃ [M + H]⁺ 378.2240, found 378.2248. IR (KBr): $\tilde{v} = 3449$, 3046, 2979, 2923, 1649, 1599, 1470, 1417, 1379, 1355, 1298, 1266, 1220, 1172, 1140, 1090, 1070, 1032, 990, 968, 896, 845, 802, 771, 750 cm⁻¹.

2-(4-Methoxyphenyl)-4-methyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (2b).

White solid (0.155 g, 76%), mp: 88 – 90 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.13 (dd, J = 7.7, 1.3 Hz, 1H), 7.47 (td, J = 7.6, 1.5 Hz, 1H), 7.40 – 7.30 (m, 4H), 6.96 – 6.90 (m, 2H), 3.96 (d, J = 12.3 Hz, 1H), 3.82 (s, 3H), 3.72 (d, J = 12.3 Hz, 1H), 1.48 (s, 3H), 1.40 (d, J = 15.7 Hz, 1H), 1.15 (s, 6H), 1.10 (s, 6H) ppm. ¹³C



NMR (100 MHz, CDCl₃): δ 164.41, 157.84, 147.93, 136.36, 132.19, 128.97, 128.36, 126.95, 126.73, 123.88, 114.27, 83.33, 77.48, 77.16, 76.84, 61.10, 55.61, 36.24, 25.98, 24.86, 24.80 ppm. HRMS (ESI): m/z calcd for C₂₄H₃₁BNO₄ [M + H]⁺ 408.2346, found 408.2333. IR (KBr): $\tilde{v} = 3449$, 2979, 2926, 1651, 1602, 1510, 1479, 1442, 1413, 1362, 1329, 1301, 1276, 1231, 1183, 1143, 1069, 1034, 871, 849, 829, 802, 771 cm⁻¹.

4-Methyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-2-(p-tolyl)-3,4dihydroisoquinolin-1(2H)-one (2c).

White solid (0.136 g, 70%), mp: 102 - 104 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.14 (dd, J = 7.7, 1.3 Hz, 1H), 7.47 (td, J = 7.6, 1.5 Hz, 1H), 7.38 (dd, J = 7.7, 0.8 Hz, 1H), 7.35 – 7.29 (m, 3H), 7.21 (d, J = 8.1 Hz, 2H), 3.99 (d, J = 12.3 Hz, 1H), 3.74 (d, J = 12.3 Hz, 1H), 2.36 (s, 3H), 1.48 (s, 3H), 1.40 (d, J = 15.5 Hz, 1H), 1.34 (d, J = 15.7

Hz, 1H), 1.15 (s, 6H), 1.10 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.29, 147.93, 140.83, 136.03, 132.20, 129.59, 129.01, 128.43, 126.73, 125.52, 123.91, 83.32, 77.48, 77.16, 76.84, 60.94, 36.27, 26.06, 24.86, 24.80, 21.16 ppm. HRMS (ESI): m/z calcd for C₂₄H₃₁BNO₃ [M + H]⁺ 392.2397, found 392.2382. IR (KBr): $\tilde{v} = 3473$, 3060, 3038, 2969, 2912, 1656, 1603, 1577, 1513, 1468, 1404, 1366, 1325, 1276, 1258, 1226, 1186, 1164, 1141, 1109, 1030, 990, 867, 849, 791, 761, 699 cm⁻¹.

2-(4-Fluorophenyl)-4-methyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (2d).

White solid (0.176 g, 89%), mp: 95 – 97 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.12 (d, J = 7.7 Hz, 1H), 7.47 (t, J = 7.5 Hz, 1H), 7.38 (dd, J = 8.3, 4.2 Hz, 3H), 7.30 (t, J = 7.7 Hz, 1H), 7.11 – 7.02 (m, 2H), 3.97 (d, J = 12.2 Hz, 1H), 3.73 (d, J = 12.3 Hz, 1H), 1.47 (s, 3H), 1.40 (d, J = 15.6 Hz, 1H), 1.30 (d, J = 15.7 Hz, 1H), 1.14 (s, 6H), 1.09 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.20, 161.78, 159.35, 147.94,



Ô

2c

Me

139.17 (d, *J* = 3.2 Hz), 132.28, 128.82, 127.90, 127.25 (d, *J* = 8.3 Hz), 126.61, 123.73, 115.64,

115.41, 83.18, 77.48, 77.16, 76.84, 60.66, 36.10, 25.58, 24.64 (d, J = 5.5 Hz) ppm. ¹⁹F NMR (471 MHz, CDCl₃): δ -115.98 ppm. HRMS (ESI): m/z calcd for C₂₃H₂₈BFNO₃ [M + H]⁺ 396.2146, found 396.2151. IR (KBr): $\tilde{v} = 3449$, 3347, 2974, 2923, 2885, 1654, 1599, 1512, 1469, 1423, 1409, 1358, 1301, 1325, 1298, 1217, 1139, 1030, 842, 770, 754, 735 cm⁻¹.

2-(4-Chlorophenyl)-4-methyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (2e).

White solid (0.152 g, 74%), mp: 88 – 90 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.12 (dd, J = 7.7, 1.1 Hz, 1H), 7.48 (td, J = 7.7, 1.3 Hz, 1H), 7.40 – 7.30 (m, 6H), 3.99 (d, J = 12.2 Hz, 1H), 3.74 (d, J = 12.2 Hz, 1H), 1.47 (s, 3H), 1.39 (d, J = 15.6 Hz, 1H), 1.30 (d, J = 15.7 Hz, 1H), 1.14 (s, 6H), 1.09 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.19, 148.01, 141.83, 132.46, 131.45, 129.00, 128.94,



127.99, 126.84, 126.78, 123.84, 83.33, 77.48, 77.16, 76.84, 60.50, 36.25, 25.80, 24.79, 24.75 ppm. HRMS (ESI): m/z calcd for C₂₃H₂₈BClNO₃ [M + H]⁺ 412.1850 found 412.1854. IR (KBr): $\tilde{v} = 3063.73$, 2989.90, 2889.50, 1654.65, 1593.16, 1496.46, 1467.95, 1421.58, 1402.68, 1327.73, 1140.60, 1088.71, 1031.73, 968.58, 843.62, 771.49, 706.27, 508.58 cm⁻¹.

4-methyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-2-(4-(4,4,5,5-

tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3,4-dihydroisoquinolin-1(2H)-one (2f).

White solid (0.156 g, 62%), mp: 168 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.15 (d, J = 7.7 Hz, 1H), 7.85 (d, J = 8.1 Hz, 2H), 7.48 (dd, J = 14.0, 4.6 Hz, 3H), 7.40 – 7.30 (m, 2H), 4.05 (d, J = 12.2 Hz, 1H), 3.78 (d, J = 12.3 Hz, 1H), 1.47 (s, 3H), 1.36 (d, J = 9.9 Hz, 14H), 1.15 (s, 6H), 1.10 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.13, 148.03, 146.07, 135.53, 132.36,



129.10, 128.34, 126.77, 124.60, 123.88, 83.92, 83.36, 77.48, 77.16, 76.84, 60.45, 36.32, 26.07, 24.96, 24.95, 24.86, 24.81 ppm. HRMS (ESI): m/z calcd for C₂₉H₄₀B₂NO₅ [M + H]⁺ 504.3092 found 504.3085. IR (KBr): $\tilde{v} = 3436.14$, 2978.03, 2927.41, 2883.40, 1656.53, 1603.88, 1467.23, 1401.47, 1361.14, 1308.72, 1275.21, 1230.35, 1143.59, 1108.92, 1093.23, 1065.79, 965.25, 861.17, 842.24, 763.19, 700.70, 661.60 ppm.

4-Methyl-2-(naphthalen-1-yl)-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (2g).

This title compound exists as a mixture of multiple rotamers. Colorless oil (0.165 g, 77%). ¹H NMR (400 MHz, CDCl₃): δ 8.21 (d, J = 7.7 Hz,1H), 7.94 – 7.82 (m, 3H), 7.58 – 7.42 (m, 6H), 7.41 – 7.35 (m, 1H), 4.15 (d, J = 12.3 Hz, 0.5H), 4.01 (d, J = 12.4 Hz, 0.5H), 3.91 (d, J = 12.4 Hz, 0.5H), 3.83 (d, J = 12.3 Hz, 0.5H), 1.58 (d, J = 4.6 Hz, 3H), 1.54 (t, J = 8.0 Hz, 1H), 1.49 – 1.40 (m, 1H), 1.26 (s, 1H), 1.21 (s, 1H),

1.17 (s, 3H), 1.11 (s, 3H), 1.06 (s, 2H), 0.98 (s, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.92, 164.86, 148.25, 140.74, 140.45, 134.67, 132.45, 129.97, 129.19, 128.66, 128.53, 128.15, 128.03, 126.84, 126.78, 126.28, 125.93, 124.78, 124.16, 124.06, 123.87, 123.67, 123.34, 83.37, 83.27, 77.48, 77.16, 76.84, 61.70, 36.41, 26.82, 26.09, 24.94, 24.93, 24.83, 24.76, 24.69, 24.67 ppm. HRMS (ESI): m/z calcd for C₂₇H₃₁BNO₃ [M + H]+ 428.2397 found 428.2395. IR (KBr): $\tilde{\nu}$ = 3409, 3061, 2977, 2929, 1662, 1599, 1509, 1474, 1418, 1361, 1326, 1270, 1225, 1141, 971, 849, 766, 700 cm⁻¹.

4-Methyl-2-(2-(prop-1-en-2-yl)phenyl)-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (2h).

Colourless oil (0.140 g, 67%). ¹H NMR (400 MHz, CDCl₃): δ 8.12 (dd, J = 7.7, 1.4 Hz, 1H), 7.47 (td, J = 7.6, 1.5 Hz, 1H), 7.38 (dd, J = 7.8, 0.9 Hz, 1H), 7.36 – 7.26 (m, 5H), 5.12 – 5.08 (m, 1H), 5.01 (s, 1H), 4.17 (d, J = 11.3 Hz, 0.3H), 3.74 (d, J = 12.2 Hz, 0.6H), 3.60 (d, J = 12.2 Hz, 0.6H), 3.35 (d, J = 11.2 Hz, 0.3H), 2.05 (s, 3H), 1.47 (s, 3H), 1.28 – 1.19 (m, 2H), 1.13 (s, 6H), 1.07 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.62, 148.11, 143.72, 141.54, 140.57, 132.11,



[] 0

2g

129.42, 128.83, 128.20, 127.35, 126.61, 123.93, 115.60, 83.19, 77.48, 77.16, 76.84, 61.07, 36.13, 24.81, 24.74, 23.69 ppm. HRMS (ESI): m/z calcd for C₂₆H₃₃BNO₃ [M + H]⁺ 418.2553, found 418.2559. IR (KBr): $\tilde{v} = 3683.29$, 3400.58, 3060.67, 2980.81, 2929.17, 1651.89, 1603.13, 1575.22, 1490.07, 1474.65, 1445.91, 1420.27, 1360.01, 1327.83 cm⁻¹.

2,4-Dimethyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4dihydroisoquinolin-1(2H)-one (2i). Colourless oil (0.132 g, 84%). ¹H NMR (400 MHz, CDCl₃): δ 7.99 (dd, J = 7.7, 1.2 Hz, 1H), 7.38 – 7.33 (m, 1H), 7.25 – 7.19 (m, 2H), 3.54 (d, J = 12.4 Hz, 1H), 3.27 (d, J = 12.4 Hz, 1H), 3.10 (s, 3H), 1.32 (s, 3H), 1.21 (s, 1H), 1.18 (s, 1H), 1.12 (s, 6H), 1.08 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.86, 147.76, 131.86, 128.42, 127.96, 126.61,



123.74, 83.35, 77.48, 77.16, 76.84, 59.58, 35.86, 35.45, 26.41, 24.90 ppm. HRMS (ESI): m/z calcd for C₁₈H₂₇BNO₃ [M + H]⁺ 315.2006, found 316.2089. IR (KBr): $\tilde{v} = 3048.24$, 2986.92, 2929.68, 1652.09, 1594.85, 1566.23, 1496.73, 1480.38, 1482.42, 1359.77, 1335.24, 1296.40, 1268.50, 1196.24, 1167.62, 1145.14, 1091.99 cm⁻¹.

2-Butyl-4-methyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4dihvdroisoquinolin-1(2H)-one (2j).

Yellow oil (0.164 g, 92%). ¹H NMR (400 MHz, CDCl₃): δ 7.99 (dd, J = 7.7, 1.3 Hz, 1H), 7.37 – 7.30 (m, 1H), 7.25 – 7.17 (m, 2H), 3.56 – 3.39 (m, 3H), 3.26 (d, J = 12.4 Hz, 1H), 1.60 – 1.51 (m, 2H), 1.36 – 1.28 (m, 5H), 1.19 (s, 1H), 1.15 (s, 1H), 1.11 (s, 6H), 1.08 (s, 6H), 0.88 (t, J = 7.4 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.19, 147.55, 131.64, 128.36, 128.14, 126.45, 123.62, 83.19, 77.48, 77.16,



76.84, 57.34, 47.06, 35.58, 29.50, 26.03, 24.83, 24.78, 20.29, 13.93 ppm. HRMS (ESI): m/z calcd for C₂₁H₃₃BNO₃ [M + H]⁺ 358.2553, found 358.2558. IR (KBr): $\tilde{v} = 3420$, 2962, 2929, 2872, 1652, 1604, 1575, 1484, 1429, 1360, 1317, 1268, 1227, 1193, 1143, 1110, 1035, 969, 848, 799, 765, 702 cm⁻¹.

2-Cyclohexyl-4-methyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4dihydroisoquinolin-1(2H)-one (2k).

Yellow oil (0.167 g, 87%). ¹H NMR (400 MHz, CDCl₃): δ 8.06 (dd, J = 7.7, 1.3 Hz, 1H), 7.42 – 7.37 (m, 1H), 7.31 – 7.25 (m, 2H), 4.68 – 4.63 (m, 1H), 3.47 (d, J = 12.5 Hz, 1H), 3.25 (d, J = 12.5 Hz, 1H), 1.81 – 1.71 (m, 5H), 1.52 – 1.39 (m, 4H), 1.37 (s, 3H), 1.24 (s, 1H), 1.23 (s, 1H), 1.19 (s, 6H), 1.17 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 163.81, 147.43, 131.68, 128.71, 126.53, 123.69, 83.28,



77.48, 77.16, 76.84, 51.88, 51.62, 35.37, 30.10, 29.94, 25.95, 25.89, 25.80, 25.73, 24.99, 24.89 ppm. HRMS (ESI): m/z calcd for $C_{23}H_{34}BNO_3$ [M + H]⁺ 384.2710, found 384.2715. IR (KBr): $\tilde{v} = 3451$, 2976, 2929, 2856, 1646, 1601, 1479, 1451, 1429, 1361, 1318, 1275, 1254, 1197, 1142, 1036, 969, 894, 849, 798, 765 cm⁻¹.

2-(Tert-butyl)-4-methyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4dihydroisoquinolin-1(2H)-one (2l).

White solid (0.161 g, 90%), mp: 71 – 73 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.05 – 8.01 (m, 1H), 7.39 – 7.35 (m, 1H), 7.28 – 7.22 (m, 2H), 3.59 (d, *J* = 12.6 Hz, 1H), 3.40 (d, *J* = 12.6 Hz, 1H), 1.54 (s, 9H), 1.35 (s, 3H), 1.25 (s, 1H), 1.21 (s, 1H), 1.20 (s, 6H), 1.17 (s, 6H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ 165.35, 147.80, 131.37, 130.25, 128.39, 126.33, 123.21, 83.21, 77.48, 77.16, 76.84, 57.03, 53.62,

35.77, 28.68, 25.36, 24.93, 24.81 ppm. HRMS (ESI): m/z calcd for C₂₁H₃₃BNO₃ [M + H]⁺ 358.2553, found 358.2553. IR (KBr): $\tilde{v} = 2979$, 2931, 2882, 1648, 1460, 1416, 1357, 1317, 1276, 1197, 1140, 1089, 965, 849, 764, 703 cm⁻¹.

2-Benzyl-4-methyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4dihydroisoquinolin-1(2H)-one (2m).

Yellow solid (0.172 g, 88%), mp: 97 – 99 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.19 – 8.14 (m, 1H), 7.48 – 7.42 (m, 1H), 7.39 – 7.26 (m, 7H), 5.18 (d, *J* = 14.4 Hz, 1H), 4.45 (d, *J* = 14.4 Hz, 1H), 3.54 (d, *J* = 12.5 Hz, 1H), 3.29 (d, *J* = 12.5 Hz, 1H), 1.25 (s, 3H), 1.21 (s, 2H), 1.16 (d, *J* = 12.8 Hz, 12H) ppm. ¹³C NMR (101 MHz, CDCl₃): δ 164.56, 147.86, 137.28, 132.00, 128.74, 128.60, 127.98, 127.50,

126.60, 123.76, 83.26, 77.48, 77.16, 76.84, 56.64, 50.73, 35.64, 26.44, 24.88, 24.85 ppm. HRMS (ESI): m/z calcd for C₂₄H₃₁BNO₃ [M + H]⁺ 392.2397, found 392.2402. IR (KBr): $\tilde{v} =$ 3436, 3067, 3030, 2975, 1645, 1600, 1568, 1484, 1451, 1430, 1382, 1358, 1320, 1298, 1261, 1208, 1190, 1141, 1092,998, 967, 847, 826, 803, 768, 739, 704 cm⁻¹.

7-Methoxy-2,4-dimethyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4dihydroisoquinolin-1(2H)-one (2n).

White solid (0.136 g, 79%), mp: 131 – 133 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.56 (d, J = 2.9 Hz, 1H), 7.19 (d, J = 8.5 Hz, 1H), 6.94 (dd, J = 8.5, 2.9 Hz, 1H), 3.79 (s, 3H), 3.54 (d, J = 12.3 Hz, 1H), 3.28 (d, J = 12.4 Hz, 1H), 3.13 (s, 3H), 1.32 (s, 3H), 1.20 (s, 1H), 1.17 (s, 1H), 1.15 (s, 6H), 1.12 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.66, 158.20, 140.06,

128.96, 125.11, 119.01, 111.55, 83.25, 77.48, 77.16, 76.84, 59.85, 55.51, 35.44, 35.25, 26.44, 24.85 ppm. HRMS (ESI): m/z calcd for $C_{19}H_{29}BNO_4$ [M + H]⁺ 346.2189, found 346.2202. IR







(KBr): $\tilde{v} = 3437, 2973, 1648, 1608, 1575, 1494, 1442, 1362, 1321, 1275, 1224, 1143, 1101, 1030, 972, 888, 850, 787, 580 cm⁻¹.$

6,7-Dimethoxy-2,4-dimethyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (2o).

White solid (0.158 g, 84%), mp: $133 - 135 \,^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): δ 7.55 (d, $J = 1.9 \,$ Hz, 1H), 6.79 (d, $J = 1.5 \,$ Hz, 1H), 3.89 (dd, $J = 5.8, 1.9 \,$ Hz, 6H), 3.59 (dd, $J = 12.3, 1.6 \,$ Hz, 1H), 3.24 (dd, $J = 12.2, 1.5 \,$ Hz, 1H), 3.12 (d, $J = 2.0 \,$ Hz, 3H), 1.32 (s, 3H), 1.24 (s, 1H), 1.18 (s, 1H), 1.15 (s, 6H), 1.11 (s,

6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.70, 151.65, 147.36, 141.32, 120.69, 110.56, 106.51, 83.30, 77.48, 77.16, 76.84, 59.96, 56.07, 55.94, 35.56, 35.35, 26.96, 24.95, 24.78 ppm. HRMS (ESI): m/z calcd for C₂₀H₃₁BNO₅ [M + H]⁺ 376.2295, found 376.2310. IR (KBr): $\tilde{v} =$ 3479, 3079, 3004, 2979, 1645, 1601, 1494, 1463, 1392, 1360, 1341, 1324, 1286, 1265, 1216, 1183, 1139, 1109, 1086, 1051, 999, 971, 881, 844, 757 cm⁻¹.

2,4-Dimethyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-6-interval (1,2,3,2-dioxaborolan-2-yl)methyl)-6-interval (1,2,3,2-dioxaborolan-2-yl)methyl-6-interval (1,2,3,2-dioxaborolan-2-interval (1,2,3,2-interval (1

(trifluoromethyl)-3,4-dihydroisoquinolin-1(2H)-one (2p).

White solid (0.172 g, 90%), mp: 54 – 55 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.16 (d, J = 8.1 Hz, 1H), 7.58 (s, 1H), 7.54 (dd, J = 8.1, 0.9 Hz, 1H), 3.59 (d, J = 12.5 Hz, 1H), 3.35 (d, J = 12.5 Hz, 1H), 3.17 (s, 3H), 1.41 (s, 3H), 1.27 (s, 2H), 1.16 (s, 6H), 1.12 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 163.49, 148.08, 133.32,

133.01, 131.12, 129.02, 125.38, 123.47 (d, J = 3.8 Hz), 122.68, 121.41 (d, J = 3.7 Hz), 83.48, 77.48, 77.16, 76.84, 59.82, 36.01, 35.53, 26.26, 24.80 (d, J = 14.5 Hz) ppm. ¹⁹F NMR (471 MHz, CDCl₃): δ -62.88 ppm. HRMS (ESI): m/z calcd for C₁₉H₂₆BF₃NO₃ [M + H]⁺ 384.1957, found 384.1956. IR (KBr): $\tilde{v} = 2979$, 1661, 1503, 1453, 1363, 1331, 1256, 1229, 1166, 1128, 1077, 969, 849, 762, 726, 702 cm⁻¹.

6-Fluoro-2,4-dimethyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4dihydroisoquinolin-1(2H)-one (2q).

Yellow oil (0.053 g, 32%). ¹H NMR (400 MHz, CDCl₃): δ 8.08 – 8.02 (m, 1H), 7.01 – 6.90 (m, 2H), 3.55 (d, *J* = 12.4 Hz, 1H), 3.33 (d, *J* = 12.4 Hz, 1H), 3.13 (d, *J* = 0.6 Hz, 3H), 1.36 (s, 3H), 1.22 (s, 1H), 1.20 (s, 1H), 1.17 (s, 6H), 1.15 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 166.31, 164.02, 163.81, 150.68 (d, *J* = 7.8

Hz), 131.21 (d, *J* = 9.3 Hz), 124.30, 113.77, 113.56, 111.15, 110.93, 83.43, 77.48, 77.16, 76.84,



ö

20

MeO

MeO



59.63, 36.02, 35.37, 26.10, 24.88 (d, J = 1.8 Hz) ppm. ¹⁹F NMR (471 MHz, CDCl₃): δ -107.72 ppm. HRMS (ESI): m/z calcd for C₁₈H₂₆BFNO₃ [M + H]⁺ 334.1989, found 334.1983. IR (KBr): $\tilde{\nu} = 3054$, 2983, 1652, 1608, 1480, 1439, 1361, 1333 cm⁻¹.

6-Fluoro-2,4,4-trimethyl-3,4-dihydroisoquinolin-1(2H)-one (2q1).

Yellow oil (0.055 g, 53%). ¹H NMR (400 MHz, CDCl₃): δ 8.06 (dd, J = 8.4, 6.1 Hz, 1H), 6.97 – 6.90 (m, 2H), 3.28 (s, 2H), 3.12 (s, 3H), 1.28 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 166.43, 163.85 (d, J = 15.5 Hz), 149.71 (d, J = 7.9 Hz), 131.30 (d, J = 9.3 Hz), 124.31 (d, J = 2.8 Hz), 113.94, 113.72, 110.60, 110.38, 77.48, 77.16, 76.84, 60.38, 35.37, 34.44

(d, J = 1.2 Hz), 26.50 ppm. ¹⁹F NMR (471 MHz, CDCl₃): δ -107.23 ppm. HRMS (ESI): m/z calcd for C₁₂H₁₅FNO [M + H]⁺ 208.1137, found 208.1587. IR (KBr): $\tilde{v} = 2971.71$, 1659.17, 1607.28, 1585.05, 1481.25, 1439.86, 1361.85, 1328.80, 1260.60, 1209.32, 1168.33, 1142.26, 1066.12, 967.83, 937.13, 893.91, 848.47, 779.86, 699.62, 606.90 cm⁻¹.

7-Chloro-2,4-dimethyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4dihydroisoquinolin-1(2H)-one (2r).

Yellow oil (0.133 g, 76%). ¹H NMR (400 MHz, CDCl₃): δ 8.01 (d, *J* = 2.3 Hz, 1H), 7.35 (dd, *J* = 8.3, 2.3 Hz, 1H), 7.23 (d, *J* = 8.3 Hz, 1H), 3.57 (d, *J* = 12.5 Hz, 1H), 3.31 (d, *J* = 12.5 Hz, 1H), 3.14 (s, 3H), 1.35 (s, 3H), 1.23 (s, 2H), 1.17 (s, 6H), 1.14 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 163.58, 146.07, 132.68, 131.65,

129.63, 128.32, 125.55, 83.43, 77.48, 77.16, 76.84, 59.48, 35.67, 35.47, 26.29, 24.89 ppm. HRMS (ESI): m/z calcd for C₁₈H₂₆BClNO₃ [M + H]+ 350.1694, found 350.1696. IR (KBr): \tilde{v} = 2977.11, 2928.05, 2859.36, 2363.86, 2340.96, 1649.22, 1606.70, 1577.27, 1493.87, 1402.29, 1330.61, 1255.11, 1096.48 cm⁻¹.

2-Methyl-4-phenyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4dihydroisoquinolin-1(2H)-one (2s).

This compound exists as a mixture of multiple rotamers. Colorless oil (0.132 g, 70%). ¹H NMR (400 MHz, CDCl₃): δ 8.11 (dd, J = 7.6, 1.3 Hz, 1H), 7.55 – 7.49 (m, 0.7H), 7.43 (td, J = 7.6, 1.5 Hz, 1.4H), 7.39 – 7.31 (m, 2H), 7.31 – 7.27 (m, 1H), 7.25 – 7.14 (m, 6H), 7.14 – 7.10 (m, 2H), 4.10 (d, J = 12.7 Hz, 1H), 3.80 (d, J = 12.7 Hz, 1H), 3.64 (s, 0.35H), 3.06 (s, 1H), 3.05 (s, 3H), 2.46 (s, 2.5H), 1.71 (d, J = 5.9 Hz,

0.25H), 1.66 (d, J = 5.1 Hz, 1.75H), 1.24 (d, J = 10.0 Hz, 1.6H), 1.10 (s, 6H), 1.04 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.80, 145.94, 132.51, 131.66, 129.33, 129.27, 128.44,



Ô

2q₁



128.27, 127.06, 127.02, 126.93, 126.64, 126.45, 126.31, 118.47, 83.43, 77.48, 77.16, 76.84, 59.19, 44.40, 43.29, 35.19, 24.82, 24.61 ppm. HRMS (ESI): m/z calcd for C₂₃H₂₉BNO₃ [M + H]⁺ 378.2240, found 378.2238. IR (KBr): $\tilde{\nu} = 3444$, 3060, 2977, 2931, 1651, 1601, 1495, 1476, 1450, 1358, 1332, 1263, 1143, 1107, 1036, 766, 701 cm⁻¹.

2-Methyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-4-(p-tolyl)-3,4dihydroisoquinolin-1(2H)-one (2t).

White solid (0.153g, 78%), mp: 91 – 93 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.16 – 8.09 (m, 1H), 7.41 (td, J = 7.5, 1.5 Hz, 1H), 7.33 (td, J = 7.5, 1.1 Hz, 1H), 7.17 (d, J = 7.7 Hz, 1H), 7.07 – 6.99 (m, 4H), 4.08 (d, J = 12.7 Hz, 1H), 3.77 (d, J = 12.7 Hz, 1H), 3.05 (s, 3H), 2.28 (s, 3H), 1.70 – 1.65 (m, 1H), 1.61 (d, J = 15.7 Hz, 1H), 1.11 (s, 6H), 1.05 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.83, 146.30, 143.01,



136.20, 131.63, 129.31, 128.97, 128.41, 126.99, 126.47, 83.41, 77.48, 77.16, 76.84, 59.28, 44.16, 35.20, 24.86, 24.64, 20.98 ppm. HRMS (ESI): m/z calcd for C₂₄H₃₁BNO₃ [M + H]⁺ 392.2319, found 392.2433. IR (KBr): $\tilde{v} = 3433$, 2977, 2926, 1653, 1601, 1496, 1476, 1455, 1357, 1264, 1216, 1193, 1143, 1079, 967, 847, 817, 766, 705 cm⁻¹.

4-(4-Fluorophenyl)-2-methyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (2u).

Colorless oil (0.158 g, 80%).¹H NMR (400 MHz, CDCl₃): δ 8.13 (dd, J = 15.1, 7.6 Hz, 1H), 7.43 (t, J = 7.1 Hz, 1H), 7.38 – 7.30 (m, 1H), 7.20 (d, J = 7.6 Hz, 1H), 7.08 (dd, J = 7.7, 5.3 Hz, 2H), 6.90 (t, J = 8.4 Hz, 2H), 4.08 (d, J = 12.8 Hz, 1H), 3.78 – 3.69 (m, 1H), 3.04 (s, 3H), 1.70 (t, J = 10.0 Hz, 0.7H), 1.64 (d, J = 4.1 Hz, 1.5H), 1.22 (s, 2.6H), 1.10 (s, 6H), 1.03 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.72,



162.70, 160.26, 145.64, 141.69, 131.78, 129.26, 128.79 – 128.36 (m), 127.23, 126.24, 115.09, 114.89, 83.50, 77.48, 77.16, 76.84, 75.09, 59.30, 43.94, 35.20, 24.87 (d, J = 11.7 Hz), 24.60 ppm. ¹⁹F NMR (471 MHz, CDCl₃): δ -116.62 ppm. HRMS (ESI): m/z calcd for C₂₃H₂₈BFNO₃ [M + H]⁺ 396.2146, found 396.2145. IR (KBr): $\tilde{v} = 3415$, 2978, 2930, 1648, 1603, 1508, 1453, 1361, 1334, 1266, 1228, 1145, 1014, 843, 704 cm⁻¹.

4-(4-Chlorophenyl)-2-methyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (2v). This compound exists as a mixture of multiple rotamers. Colourless oil (0.109 g, 53%). ¹H NMR (400 MHz, CDCl₃): δ 8.17 (dd, J = 7.7, 1.3 Hz, 0.6H), 8.13 (dd, J = 7.7, 1.1 Hz, 1H), 7.49 – 7.42 (m, 2H), 7.41 – 7.28 (m, 5H), 7.25 – 7.18 (m, 5H), 7.11 – 7.05 (m, 4H), 4.11 (d, J = 12.8 Hz, 1H), 3.75 (dd, J = 12.7, 6.2 Hz, 1.5H), 3.57 (d, J = 12.7 Hz, 0.6H), 3.15 (s, 0.7H), 3.06 (s, 4.8H), 1.73 (d, J = 12.7 Hz, 2.3H), 1.65 (d, J = 7.6 Hz, 1.5H), 1.25 (d, J = 10.1 Hz, 2.5H), 1.12 (s, 6H), 1.05

(s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.68, 164.47, 145.33, 144.91, 144.64, 143.72, 132.86, 132.50, 132.15, 131.81, 129.29, 129.23, 128.75, 128.60, 128.50, 128.37, 127.53, 127.32, 126.26, 125.85, 84.18, 83.54, 77.48, 77.16, 76.84, 60.91, 59.16, 44.10, 42.56, 35.38, 35.23, 25.66, 24.95, 24.83, 24.62 ppm. HRMS (ESI): m/z calcd for C₂₃H₂₈BClNO₃ [M + H]⁺ 412.1850, found 412.1868. IR (KBr): $\tilde{\nu} = 2971.11$, 2928.05, 2859.36, 2363.86, 2340.96, 1649.22, 1606.70, 1577.27, 1493.87, 1402.29, 1333.61, 1274.73, 1255.11, 1142.27, 1096.48, 1013.08 cm⁻¹.

2,4-Dimethylisoquinolin-1(2H)-one (4a).

White solid (0.072 g, 83%), mp: 59 – 60 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.41 (dd, J = 8.0, 0.8 Hz, 1H), 7.63 – 7.57 (m, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.46 – 7.40 (m, 1H), 6.83 – 6.76 (m, 1H), 3.49 (s, 3H), 2.17 (d, J = 0.9 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 162.23, 137.27, 131.80, 130.17,

127.89, 126.51, 125.81, 122.97, 111.85, 77.48, 77.16, 76.84, 36.63, 15.23 ppm. . HRMS (ESI): m/z calcd for C₁₁H₁₂NO [M + H]⁺ 174.0918, found 174.0916. IR (KBr): $\tilde{v} = 2965$, 2902, 2863, 2744, 1651, 1629, 1598, 1473, 1491, 1444, 1417, 1356, 1328, 1178, 1069, 1046, 1026, 838, 801, 772, 745 cm⁻¹.

4-Methyl-2-(2-methylallyl)isoquinolin-1(2H)-one (4b).

Colorless oil (0.066 g, 62%). ¹H NMR (400 MHz, CDCl₃): δ 8.41 – 8.40 (m, 1H), 7.63 – 7.59 (m, 1H), 7.52 (d, *J* = 8.0 Hz, 1H), 7.45 – 7.40 (m, 1H), 6.77 (d, *J* = 1.1 Hz, 1H), 4.88 – 4.85 (m, 1H), 4.72 – 4.69 (m, 1H), 4.48 (s, 2H), 2.20 (d, *J* = 1.2 Hz, 3H), 1.68 – 1.65 (m, 3H) ppm. ¹³C NMR



(100 MHz, CDCl₃): δ 161.96, 140.95, 137.37, 132.16, 128.77, 128.52, 126.74, 126.09, 123.13, 113.07, 112.23, 77.48, 77.16, 76.84, 53.20, 20.10, 15.48 ppm. HRMS (ESI): m/z calcd for C₁₄H₁₆NO [M + H]⁺ 214.1231, found 214.1221. IR (KBr): $\tilde{v} = 3064$, 2974, 2925, 1693, 1657, 1628, 1603, 1488, 1441, 1374, 1318, 1169, 1124, 900, 848, 768 cm⁻¹.





2-(2-Methylallyl)-4-phenyl-4-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4dihydroisoquinolin-1(2H)-one (4c).

Colourless oil (0.121 g, 58%). ¹H NMR (400 MHz, CDCl₃): δ 8.13 – 7.97 (m, 0.9H), 7.46 (dd, J = 7.2, 1.2 Hz, 0.9H), 7.43 – 6.93 (m, 7H), 5.50 (s, 0.4H), 5.22 (t, J = 7.2 Hz, 0.8H), 4.69 (d, J = 20.7 Hz, 0.2H), 4.36 – 4.24 (m, 0.1H), 4.14 (d, J = 15.1 Hz, 0.6H), 4.02 – 3.87 (m, 0.2H), 3.61 (dd, J = 13.6, 4.1 Hz, 0.2H), 3.42 (dt, J = 17.4, 5.8 Hz, 0.8H), 3.28 – 3.09 (m, 1H), 3.03 (d, J = 12.4 Hz, 0.2H), 1.30 – 0.93 (m,



17H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.75, 164.35, 147.77, 144.03, 138.26, 131.94, 128.64, 128.46, 128.04, 127.81, 127.48, 127.40, 126.47, 123.71, 115.92, 83.26, 77.48, 77.16, 76.84, 55.26, 49.92, 35.52, 26.87, 24.86, 19.62 ppm. HRMS (ESI): m/z calcd for C₂₆H₃₃BNO₃ [M + H]⁺ 418.2553, found 418.2571. IR (KBr): $\tilde{\nu} = 3439$, 2976, 2926, 1651, 1483, 1359, 1329, 1262, 1143, 764, 701 cm⁻¹.

1-(3-Methyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)indolin-1-yl)ethan-1-one (6a).

White solid (0.142 g, 90%), mp: 68 – 70 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.07 (d, J = 8.1 Hz, 1H), 7.08 (t, J = 7.6 Hz, 2H), 6.94 (t, J = 7.4 Hz, 1H), 3.99 (d, J = 10.2 Hz, 1H), 3.68 (d, J = 10.2 Hz, 1H), 2.14 (s, 3H), 1.31 (s, 3H), 1.18 (d, J = 2.5 Hz, 1H), 1.16 (d, J = 2.1 Hz, 1H), 1.03 (s, 12H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 168.76,



141.57, 140.94, 127.56, 123.76, 122.15, 116.90, 83.23, 77.48, 77.16, 76.84, 62.90, 41.56, 29.88, 24.88, 24.80, 24.69, 24.31 ppm. HRMS (ESI): m/z calcd for C₁₈H₂₇BNO₃ [M + H]⁺ 316.2084, found 316.2092. IR (KBr): $\tilde{v} = 3058.53$, 2972.59, 2924.89, 2744.69, 1982.18, 1862.14, 1761.89, 1621.69, 1587.10, 1502.03, 1319.78, 1272.98, 1240.80, 1196.95, 1133.74, 1113.44, 1072.25, 1055.02, 926.01, 814.04, 602.35 cm⁻¹.

1-(3,5-Dimethyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)indolin-1yl)ethan-1-one (6b).

White solid (0.140 g, 85%), mp: 89 – 91 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.99 (d, J = 7.9 Hz, 1H), 7.04 – 6.90 (m, 2H), 4.01 (d, J = 10.2 Hz, 1H), 3.71 (d, J = 10.3 Hz, 1H), 2.27 (s, 3H), 2.18 (s, 3H), 1.35 (s, 2.5H), 1.31 (s, 0.5 H) 1.22 (t, J = 13.3 Hz, 2H), 1.13 (d, J = 9.1 Hz, 2H), 1.09 (s, 10H). ppm. ¹³C NMR (100 MHz,



CDCl₃): δ 168.39, 141.01, 139.30, 133.20, 128.03, 122.77, 116.62, 83.21, 77.48, 77.16, 76.84, 63.11, 41.51, 29.75, 24.83, 24.67, 24.21, 21.17 ppm. HRMS (ESI): m/z calcd for C₁₉H₂₉BNO₃ [M + H]⁺ 330.2440, found 330.2282. IR (KBr): $\tilde{v} = 2976$, 2919, 1666, 1612, 1591, 1489, 1390, 1326, 1273, 1213, 1142, 847, 822 cm⁻¹.

1-(5-Chloro-3-methyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)indolin-1yl)ethan-1-one (6c).

White solid (0.152 g, 87%), mp: 102 – 103 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.06 (d, J = 9.2 Hz, 1H), 7.12 – 7.07 (m, 2H), 4.03 (d, J = 10.2 Hz, 1H), 3.74 (d, J = 10.2 Hz, 1H), 2.19 (s, 3H), 1.37 (s, 3H), 1.22 (s, 1H), 1.19 (s, 1H), 1.12 (s, 6H), 1.11 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 168.81, 142.92, 140.32, 128.54, 127.53, 122.69, 117.92, 83.42, 77.48, 77.16, 76.84,



63.25, 41.71, 29.58, 24.86, 24.74, 24.20 ppm. HRMS (ESI): m/z calcd for $C_{18}H_{26}BrClNO_3$ [M + H]⁺ 350.1694, found 350.1704. IR (KBr): $\tilde{v} = 3317.77$, 3113.64, 2981.15, 2929.28, 2873.80, 1671.09, 1667.41, 1595.33, 1478.70, 1394.02, 1331.87, 1263.66, 1213.80 cm⁻¹.

1-(5-Fluoro-3-methyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)indolin-1yl)ethan-1-one (6d).

White solid (0.147 g, 88%), mp: 70-72 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.13 – 8.07 (m, 1H), 6.87 – 6.81 (m, 2H), 4.05 (d, J = 10.3 Hz, 1H), 3.77 (d, J = 10.3 Hz, 1H), 2.20 (s, 3H), 1.38 (s, 3H), 1.23 (s, 1H), 1.21 (s, 1H), 1.12 (d, J = 1.2 Hz, 12H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 168.5, 160.86, 158.46, 143.09,



137.73, 117.88 (d, J = 8.0 Hz), 113.99, 113.76, 109.76, 109.52, 83.46, 77.48, 77.16, 76.84, 63.28, 41.72, 29.60, 24.83 (d, J = 11.8 Hz), 24.16 ppm. ¹⁹F NMR (471 MHz, CDCl₃) δ -119.04 ppm. HRMS (ESI): m/z calcd for C₁₈H₂₆BFNO₃ [M + H]⁺ 334.1989, found 334.2000. IR (KBr): $\tilde{\nu} = 2981.26$, 2929.64, 2878.99, 2358.95, 2331.15, 1667.42, 1607.85, 1485.02, 1403.97, 1362.38, 1337.84, 1277.33, 1275.56, 1271.91, 1264.05, 1256.35, 1214.45, 1184.10, 1167.18, 1142.33, 1022.79 cm⁻¹.

4,4,5,5-Tetramethyl-2-((3-methyl-2,3-dihydrobenzofuran-3-yl)methyl)-1,3,2dioxaborolane (6e).

Colorless oil (0.104 g, 76%). ¹H NMR (400 MHz, CDCl₃): δ 7.17 – 7.13 (m, 1H), 7.12 – 7.06 (m, 1H), 6.85 (td, J = 7.4, 1.0 Hz, 1H), 6.78 – 6.73 (m, 1H), 4.42 (d, J = 8.6 Hz, 1H), 4.26 (d, J = 8.6 Hz, 1H), 1.37 (s, 3H), 1.31 (d, J = 15.5 Hz, 1H), 1.24 (d, J = 11.3 Hz, 1H), 1.20 (s,



6H), 1.19 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 159.12, 137.49, 127.84, 122.74, 120.51, 109.59, 84.23, 83.33, 77.47, 77.16, 76.84, 43.29, 28.21, 24.92, 24.87 ppm. HRMS (ESI): m/z calcd for C₁₆H₂₄BO₃ [M + H]⁺ 275.1818, found 275.1824. IR (KBr): $\tilde{v} = 2976$, 1599, 1478, 1362, 1324, 1262, 1212, 1144, 1103, 1017, 976, 845, 804, 748 cm⁻¹.

1-Methyl-3-phenyl-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)indolin-2-one (6f)¹⁷.

Colorless oil (0.136 g, 78%). ¹H NMR (400 MHz, CDCl₃): δ 7.35 – 7.17 (m, 6H), 7.07 (t, *J* = 7.5 Hz, 1H), 6.87 (d, *J* = 7.7 Hz, 1H), 3.21 (s, 3H), 1.99 (d, *J* = 15.2 Hz, 1H), 1.87 (d, *J* = 15.1 Hz, 1H), 0.97 (s, 6H), 0.86 (s, 6H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 179.74, 144.57, 141.95, 134.43, 128.47, 128.13, 127.09, 126.72, 124.86, 122.52, 108.05, 83.19, 77.48, 77.16, 76.84, 53.21, 26.65, 24.78, 24.34 ppm. HRMS (ESI): m/z



calcd for C₂₂H₂₇BNO₃ [M + H]⁺ 364.2084, found 364.2163. IR (KBr): $\tilde{v} = 3433$, 2976, 2930, 1718, 1649, 1608, 1491, 1468, 1352, 1266, 1210, 1143, 1076, 1027, 966, 936, 883, 850, 803, 752 cm⁻¹.

 $((4-Methyl-1-oxo-2-phenyl-1,2,3,4-tetrahydroisoquinolin-4-yl) methyl) boronic \ acid \ (7a)$

White solid (0.125 g, 80%). mp: 164 °C. ¹H NMR (400 MHz, DMSO): δ 7.94 (d, J = 7.1 Hz, 1H), 7.67 (s, 2H), 7.55 (d, J = 6.8 Hz, 1H), 7.42 (s, 4H), 7.26 (s, 1H), 3.99 (d, J = 12.1 Hz, 1H), 3.79 (d, J = 12.1 Hz, 1H), 1.42 (s, 3H), 1.19 (s, 2H) ppm. ¹³C NMR (100 MHz, DMSO): δ 162.97, 149.32, 143.47, 132.33, 128.73, 127.97, 127.82, 126.21, 125.91, 125.60, 124.03, 59.70, 40.12, 39.92, 39.71, 39.50, 39.29, 39.08, 38.87, 35.93,



25.43 ppm. HRMS (ESI): m/z calcd for $C_{17}H_{19}BNO_3$ [M + H]⁺ 296.1458, found 296.1457. IR (KBr): $\tilde{v} = 3326, 2976, 2901, 2882, 1642, 1596, 1572, 1480, 1451, 1420, 1366, 1329, 1266, 1236, 1092, 1043, 961, 908, 818, 780, 730, 606 cm⁻¹.$

4-(hydroxymethyl)-4-methyl-2-phenyl-3,4-dihydroisoquinolin-1(2H)-one (7b)

White solid (0.130 g, 92%). mp: 148 – 151 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.15 (dd, J = 7.8, 1.3 Hz, 1H), 7.51 (td, J = 7.6, 1.4 Hz, 1H), 7.41 – 7.34 (m, 1H), 7.32 (dd, J = 8.5, 1.8 Hz, 4H), 7.30 – 7.27 (m, 1H), 7.20 – 7.16 (m, 1H), 3.87 (d, J = 12.5 Hz, 1H), 3.73 – 3.64 (m, 2H), 3.41 (dd, J = 10.9, 4.5 Hz, 1H), 3.09 (s, 1H), 1.34 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ 164.00, 143.35, 142.78, 132.49, 129.13, 129.03, 128.96, 127.38, 126.55, 125.83, 124.63, 67.08, 56.20, 39.65, 20.28 ppm. HRMS (ESI): m/z calcd for C₁₇H₁₉BNO₃ [M + H]+ 268.1337, found 268.1344. IR (KBr): ṽ = 3413, 3052, 2968, 2900, 2870, 1639, 1597, 1571, 1494, 1458, 1427, 1405, 1334, 1263, 1227, 1062, 1028, 761, 734, 697 cm⁻¹.
9. Table S2. Crystal data for compounds [Pd(C∧C:)(PPh₃)Cl] and 20

$[Pd(C \land C:)(PPh_3)Cl] \qquad 20$

empirical formula	C43 H41 Cl N5 O3 P Pd	C ₂₀ H ₃₀ B N O ₅
formula wt	848.63	375.26
temp (K)	293(2)0	293(2)
cryst syst	Monoclinic	Monoclinic
space group	P 21/a	P 21/c
<i>a</i> (Å)	9.5617(4)	9.3411(14)
<i>b</i> (Å)	39.7290(15)	10.4942(16)
<i>c</i> (Å)	10.2744(4)	21.238(4)
α (deg)	90	90
β (deg)	92.477(3)	88.740(14)
γ (deg)	90	90
$V(\text{\AA}^3)$	3899.4(3)	2081.5(6)
Ζ	4	4
ρ calcd (Mg m ⁻³)	1.446	1.197
μ (mm ⁻¹)	0.632	0.084
<i>F</i> (000)	1744	808
cryst size (mm)	0.55 x 0.14 x 0.08	0.84 x 0.72 x 0.48
θ range (deg)	3.929 - 29.104	3.468 - 29.578
no. of collected/unique	29580 / 9220	22829 / 5058
rflns	(R(int) = 0.0785)	(R(int) = 0.0342)
no. of data/restraints/	9220 / 0 / 481	5058 / 0 / 252
params		
$R1, wR2 (I > 2\sigma(I))^a$	0.1159, 0.2262	0.0571, 0.1346
<i>R</i> 1, <i>wR</i> 2 (all data) ^{a}	0.1401, 0.2373	0.0884, 0.1554

GOF 1.060 1.033 $\Delta \rho \max \Delta \rho \min (e \ \text{\AA}^{-3})$ 1.243/-3.942 0.394/-0.219 ${}^{a}R1 = \sum ||Fo| - |Fc|| / \sum |Fo|; \ wR2 = [\sum w (Fo^{2} - Fc^{2})^{2} / \sum w (Fo^{2})^{2}]^{0.5}.$

10. REFERENCES

1. (a) P. Keshri, K.-R. Bettadapur, V. Lanke, K.-R. Prabhu, Ru(II)-Catalyzed C-H Activation: Amide-Directed 1,4-Addition of the Ortho C-H Bond to Maleimides. J. Org. Chem., 2016, **81**, 6056 – 6065. (b) J. Hu, T.-J. Pu, Z.-W. Xu, W.-Y. Xu, Y.-S. Feng, Cadmium Sulfide Quantum-Dot-Photocatalyzed Cascade Cyclization of Functionalized Difluoromethyl Chlorides with Unactivated Olefins. Adv. Synth. Catal., 2019, **361**, 708-713.

- A. Gogoi, S. Guin, S.-K. Rout, G. Majji, B.-K. Patel, A Cu-catalysed synthesis of substituted 3-methyleneisoindolin-1-one. RSC Adv., 2014, 4, 59902 – 59907.
- Y. Long, Z. She, X. Liu, Y. Chen, Synthesis of 1-Aminoisoquinolines by Gold(III)-Mediated Domino Reactions from 2-Alkynylbenzamides and Ammonium Acetate. J. Org. Chem., 2013, 78, 2579 – 2588.
- S.-J. Balkrishna, B.-S. Bhakuni, D. Chopra, S. Kumar, Cu-Catalyzed Efficient Synthetic Methodology for Ebselen and Related Se-N Heterocycles. Org. Lett., 2010, 12, 5394 – 5397.
- H. Liu, W. Han, C. Li, Z. Ma, R. Li, X. Zheng, H. Fu, H. Chen, Practical Synthesis of Phenanthridinones by Palladium-Catalyzed One-Pot C–C and C–N Coupling Reaction: Extending the Substrate Scope to o-Chlorobenzamides. Eur. J. Org. Chem., 2016, 389 – 393.
- J. Jin, K. Zhang, F. Dou, C. Hao, Y. Zhang, X. Cao, L. Gao, J. Xiong, X. Liu, B. Liu, G. Zhang, Y. Chen, Isoquinolinone derivatives as potent CNS multi-receptor D2/5-HT1A/5-HT2A/5-HT6/5-HT7 agents: Synthesis and pharmacological evaluation. Eur. J. Med. Chem., 2020, 207, 112709.
- 7. G. Pallikonda, C.-Y. Hsieh, H.-L. Su, J-C. Hsieh, A combined pathway for the synthesis of nitidine family alkaloids. Research on Chemical Intermediates. 2019, **45**, 5399 5407.
- 8. K. Xu, S. Yang, Z. Ding, PhI(OAc)2-mediated oxidative rearrangement of allylic amides: efficient synthesis of oxazoles and β -keto amides. Org. Chem. Front., 2020, **7**, 69 72.
- M. Zhang, X. Ding, A. Lu, J. Kang, Y. Gao, Z. Wang, H. Li, Q. Wang, Generation and precise control of sulfonyl radicals: visible-light-activated redox-neutral formation of sulfonates and sulfonamides. Org. Chem. Front., 2021, 8, 961 – 967.

- 10. M. Wasa, J.-Q. Yu, Synthesis of β-, γ-, and δ-Lactams via Pd(II)-Catalyzed C–H Activation Reactions. J. Am. Chem. Soc., 2008, **130**, 14058 14059.
- D.-S. Chung, J.-S. Lee, H. Ryu, J. Park, H. Kim, J.-H. Lee, U.-B. Kim, W.-K. Lee, M.-H. Baik, S. Lee, Palladium-Catalyzed Divergent Cyclopropanation by Regioselective Solvent-Driven C(sp3)@H Bond Activation. Angew. Chem. Int. Ed., 2018, 57, 15460 15464.
- S.-G. Newman, J.-K. Howell, N. Nicolaus, M. Lautens, Palladium-Catalyzed Carbohalogenation: Bromide to Iodide Exchange and Domino Processes. J. Am. Chem. Soc., 2011, 133, 14916 – 14919.
- A. Bunescu, T. Piou, Q. Wang, J. Zhu, Pd-Catalyzed Dehydrogenative Aryl–Aryl Bond Formation via Double C(sp2)–H Bond Activation: Efficient Synthesis of [3,4]-Fused Oxindoles. Org. Lett., 2015, 17, 334 – 337.
- C. Cheng, B. Wan, B. Zhou, Y. Gu, Y. Zhang, Enantioselective synthesis of quaternary 3,4-dihydroisoquinolinones via Heck carbonylation reactions: development and application to the synthesis of Minalrestat analogues. Chem. Sci., 2019, **10**, 9853 – 9858.
- 15. L. Zhou, S. Li, B. Xu, D. Ji, L. Wu, Y. Liu, Z.-M. Zhang, J. Zhang, Enantioselective Difunctionalization of Alkenes by a Palladium-Catalyzed Heck/Sonogashira Sequence. Angew. Chem. Int. Ed., 2020, 59, 2769 – 2775.
- 16. X. Luo, L. Zhou, H. Lu, G. Deng, Y. Liang, C. Yang, Y. Yang, Palladium-Catalyzed Domino Heck/C–H Activation/Decarboxylation: A Rapid Entry to Fused Isoquinolinediones and Isoquinolinones. Org. Lett., 2019, 21, 9960–9964.
- A. Whyte, K.-I. Burton, J. Zhang, M. Lautens, Enantioselective Intramolecular Copper-Catalyzed Borylacylation. Angew. Chem. Int. Ed., 2018, 57, 13927 – 13930.

11. NMR Spectra

¹H NMR-spectrum (400 MHz, DMSO-d₆) of ImidHCl







¹H NMR-spectrum (400 MHz, CDCl₃) of [Pd(CAC:)PPh₃Cl]



³¹P NMR spectrum (162 MHz, CDCl₃) of [Pd(CAC:)PPh₃Cl]



ESI Spectrum of [Pd(CAC:)PPh₃Cl]


¹H NMR-spectrum (400 MHz, CDCl₃) of 1a







¹³C NMR-spectrum (100 MHz, CDCl₃) of 1b





 ^1H NMR-spectrum (400 MHz, CDCl_3) of 1c





¹³C NMR-spectrum (100 MHz, CDCl₃) of 1c



¹H NMR-spectrum (400 MHz, CDCl₃) of 1d





¹³C NMR-spectrum (100 MHz, CDCl₃) of 1d



¹⁹F NMR-spectrum (471 MHz, CDCl₃) of **1d**





^1H NMR-spectrum (400 MHz, CDCl_3) of 1e





¹³C NMR-spectrum (100 MHz, CDCl₃) of 1e



 ^{13}C NMR-spectrum (100 MHz, CDCl₃) of 1f



¹³C NMR-spectrum (100 MHz, CDCl₃) of 1g



¹³C NMR-spectrum (100 MHz, CDCl₃) of 1h





¹³C NMR-spectrum (100 MHz, CDCl₃) of 1i



¹³C NMR-spectrum (100 MHz, CDCl₃) of 1j





¹³C NMR-spectrum (100 MHz, CDCl₃) of 1k



¹³C NMR-spectrum (100 MHz, CDCl₃) of 11





¹³C NMR-spectrum (100 MHz, CDCl₃) of 1m



¹³C NMR-spectrum (100 MHz, CDCl₃) of 1n







¹³C NMR-spectrum (100 MHz, CDCl₃) of 10



¹³C NMR-spectrum (100 MHz, CDCl₃) of 1p



¹H NMR-spectrum (400 MHz, CDCl₃) of **1**q



¹³C NMR-spectrum (100 MHz, CDCl₃) of 1q



¹⁹F NMR-spectrum (471 MHz, CDCl₃) of 1q







¹³C NMR-spectrum (100 MHz, CDCl₃) of 1r



¹³C NMR-spectrum (100 MHz, CDCl₃) of 1s



¹³C NMR-spectrum (100 MHz, CDCl₃) of 1t



¹³C NMR-spectrum (100 MHz, CDCl₃) of 1u



¹H NMR-spectrum (400 MHz, CDCl₃) of 1v

7.133395 7.15550 7.15550 7.15551 7.15551 7.15551 7.1519 7.1519 7.1519 7.1519 7.1519 7.1519 7.1519 7.1519 7.1514 7.15551 7.1514 7.144 7.1514 7.1



¹³C NMR-spectrum (100 MHz, CDCl₃) of 1v



¹H NMR-spectrum (400 MHz, CDCl₃) of 1aa



¹H NMR-spectrum (400 MHz, CDCl₃) of **1ab**

8.000000 8.000000 8.000000 8.000000 8.000000 8.000000



¹³C NMR-spectrum (100 MHz, CDCl₃) of 1ab



 ^1H NMR-spectrum (400 MHz, CDCl_3) of 1ac





^{13}C NMR-spectrum (100 MHz, CDCl₃) of 1ac



¹H NMR-spectrum (400 MHz, CDCl₃) of **3a**

7.5.680 7.5.680 7.5.681 7.5.682



¹³C NMR-spectrum (100 MHz, CDCl₃) of **3a**



¹H NMR-spectrum (400 MHz, CDCl₃) of **3b**





¹H NMR-spectrum (400 MHz, CDCl₃) of 3c

7.1112 7.1098 7.0094 7.0007 7.0005 7.0005 7.0005 7.0005 7.0052 7.0052 7.0052 7.0052 7.0052 7.0052 7.2012 5.2232 5.2241 5.2241 5.2241 5.2241 5.2243 5.2445 5. 590 566 82. ¥. 467.



¹³C NMR-spectrum (100 MHz, CDCl₃) of 3c



¹H NMR-spectrum (400 MHz, CDCl₃) of 2a





¹³C NMR-spectrum (100 MHz, CDCl₃) of 2a



 1H NMR-spectrum (400 MHz, CDCl₃) of 2b





¹H NMR-spectrum (400 MHz, CDCl₃) of 2c





¹³C NMR-spectrum (100 MHz, CDCl₃) of 2c



¹H NMR-spectrum (400 MHz, CDCl₃) of 2d





¹³C NMR-spectrum (100 MHz, CDCl₃) of 2d



¹⁹F NMR-spectrum (471 MHz, CDCl₃) of 2d





^1H NMR-spectrum (400 MHz, CDCl_3) of 2e




^{13}C NMR-spectrum (100 MHz, CDCl₃) of 2f







¹³C NMR-spectrum (100 MHz, CDCl₃) of 2g



¹³C NMR-spectrum (100 MHz, CDCl₃) of **2h**



¹³C NMR-spectrum (100 MHz, CDCl₃) of 2i



¹³C NMR-spectrum (100 MHz, CDCl₃) of 2j



¹³C NMR-spectrum (100 MHz, CDCl₃) of 2k



¹³C NMR-spectrum (100 MHz, CDCl₃) of 2l



¹³C NMR-spectrum (100 MHz, CDCl₃) of 2m



10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 f1 (ppm) 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5

0.0

¹³C NMR-spectrum (100 MHz, CDCl₃) of 2n



¹³C NMR-spectrum (100 MHz, CDCl₃) of 20





¹³C NMR-spectrum (100 MHz, CDCl₃) of **2p**















arp50821 sd-02 F19CPD CDCl3 /opt/topspin nmr 1 



$^1\!H$ NMR-spectrum (400 MHz, CDCl₃) of $2q_1$

MJR-II-94 PROTON_PU CDCl3 {D:\NDR} CIF_NMR	C8.0742 8.0592 8.0592 8.0593 8.0593 7.52598 6.52595 7.52595 7.53559 7.53559 7.53559 7.535959 7.555957 7.555957 7.555957 7.555957 7.555957 7.555957 7.555957 7.555957 7.555957 7.555957 7.555957 7.555957 7.555977 7.555977 7.5559777 7.5559777 7.55597777777777	-3.2763	- 1.2814
		1 (



¹³C NMR-spectrum (100 MHz, CDCl₃) of 2q1





¹⁹F NMR-spectrum (471 MHz, CDCl₃) of 2q1

arp50821 sd-04 F19CPD CDCl3 /opt/topspin nmr 14

20 10



¹H NMR-spectrum (400 MHz, CDCl₃) of 2r



¹³C NMR-spectrum (100 MHz, CDCl₃) of 2r

MJR-II-93 C13CPD_PU CDCI3 {D:\NDR} CIF_NMR 1 25 00 01	- 146.0747 - 132.6830 - 132.6830 - 131.6476 - 129.6307 - 129.6307 - 128.3181	-83.4262 -77.4774 -77.1599 -76.8415	- 59.4760	- 35.6654 - 35.4729 - 26.2940 - 24.8883
		$\sim \rightarrow$		\rightarrow γ







¹³C NMR-spectrum (100 MHz, CDCl₃) of 2s



¹H NMR-spectrum (400 MHz, CDCl₃) of 2t



¹H NMR-spectrum (400 MHz, CDCl₃) of **2u**



¹³C NMR-spectrum (100 MHz, CDCl₃) of 2u



¹⁹F NMR-spectrum (471 MHz, CDCl₃) of 2u





¹H NMR-spectrum (400 MHz, CDCl₃) of 2v





¹³C NMR-spectrum (100 MHz, CDCl₃) of 2v





¹³C NMR-spectrum (100 MHz, CDCl₃) of 4a





¹³C NMR-spectrum (100 MHz, CDCl₃) of 4b





¹³C NMR-spectrum (100 MHz, CDCl₃) of 4c





¹³C NMR-spectrum (100 MHz, CDCl₃) of 6a



¹³C NMR-spectrum (100 MHz, CDCl₃) of **6b**





¹³C NMR-spectrum (100 MHz, CDCl₃) of 6d







¹H NMR-spectrum (400 MHz, CDCl₃) of 6e



¹H NMR-spectrum (400 MHz, CDCl₃) of 6f



¹H NMR-spectrum (400 MHz, DMSO) of 7a



¹³C NMR-spectrum (100 MHz, DMSO) of 7a



¹H NMR-spectrum (400 MHz, CDCl₃) of 7b





- 1.34





¹³C NMR-spectrum (100 MHz, CDCl₃) of 7b

MJR-935 C13CPD CDCl3 {D:\NDR} CIF_NMR 1	164.00	143.35 142.78 132.49 129.13 129.03 129.03 125.33 125.83 124.63 124.63	77.48 77.16 76.84 67.08	56.20	39.65	20.28
			\checkmark \downarrow		1	1

